

# Dineo Khabele, MD, FACOG, FACS

2/25/2026

## **Contact Information**

### Office Address

Department of Obstetrics and Gynecology  
WashU Medicine  
660 S. Euclid Ave, Mailstop 8064-37-1005  
St. Louis, MO 63110

Phone (314) 362-7139

Fax: (314) 362-0041

Email – [khabeled@wustl.edu](mailto:khabeled@wustl.edu)

## **Present Position**

- 6/2020 - present      Mitchell & Elaine Yanow Professor and Head  
Investigator Track with Tenure  
Department of Obstetrics and Gynecology
- 6/2020 - present      Professor (Investigator Track), Secondary Appointment  
Department of Biochemistry and Molecular Biophysics

## **Education**

### Undergraduate/Graduate

8/1985 - 5/1989      BA - Premedical Studies and Political Science  
Columbia College, Columbia University, New York, NY

### Graduate

8/1990 - 5/1994      MD – Medicine  
College of Physicians and Surgeons  
Columbia University, New York, NY

### Post-graduate training

The New York Presbyterian Hospital,  
Weill-Cornell University Medical Center  
New York, NY

7/1994 - 6/1997      Residency, Obstetrics and Gynecology

7/1997 - 6/1998      Chief Residency, Obstetrics and Gynecology

Albert Einstein College of Medicine and Montefiore Medical Center  
Bronx, NY

- 7/1998 - 6/2001 Fellowship, Gynecologic Oncology (Mentors: Gary L. Goldberg, MD, and Carolyn D. Runowicz, MD)
- 7/2001 - 6/2004 Research Fellowship, Cancer Biology (Ovarian Cancer)  
(Mentors: Raju Kucherlapati, PhD and Leonard Augenlicht, PhD)

### **Academic and Promotion History:**

#### Albert Einstein College of Medicine, Bronx, NY

- 7/2001 - 6/2004 Assistant Professor  
Department of Obstetrics & Gynecology and Women's Health
- 7/2002 - 6/2004 Laboratory Director  
Molecular Genetics and Translational Research Program for  
Women's Cancers and Other Disorders
- 7/2004 - 6/2011 Adjunct Assistant Professor  
Department of Obstetrics & Gynecology and Women's Health

#### Meharry Medical College, Nashville, TN

- 8/2004 - 6/2008 Assistant Professor  
Department of Obstetrics and Gynecology Director  
Division of Gynecologic Oncology
- 8/2004 - 6/2008 Director  
Women's Cancer Research Laboratory  
Department of Obstetrics and Gynecology
- 10/2008-12/2014 Adjunct Assistant Professor  
Department of Obstetrics and Gynecology
- 1/2015 - 3/2017 Adjunct Associate Professor  
Department of Obstetrics and Gynecology

#### Vanderbilt University, Nashville, TN

- 7/2005 - 6/2008 Adjunct Clinical Instructor  
Department of Obstetrics and Gynecology
- 7/2005 - 6/2008 Adjunct Assistant Professor  
Department of Cancer Biology
- 7/2008 - 12/2014 Assistant Professor  
Department of Obstetrics and Gynecology
- 7/2008 - 12/2014 Assistant Professor  
Department of Cancer Biology
- 7/2008 - 3/2017 Member  
Vanderbilt-Ingram Cancer Center, Genome Maintenance Program
- 7/2008 - 3/2017 Director  
Gynecologic Oncology Translational Research  
Department of Obstetrics and Gynecology
- 6/2014-3/2017 Co-founder and Leader

1/2015-3/2017 Vanderbilt Ovarian Cancer Alliance (VOCAL)  
Associate Professor  
Department of Obstetrics and Gynecology  
1/2015-3/2017 Associate Professor  
Department of Cancer Biology

The Broad Institute of MIT and Harvard, Cambridge, MA

7/2008 - 8/2014 Visiting Faculty  
Chemical Biology Program

The University of Kansas School of Medicine, Kansas City, KS

5/2017 - 4/2020 Professor  
Department of Obstetrics and Gynecology  
5/2017 - 4/2020 Director, Division of Gynecologic Oncology  
Department of Obstetrics and Gynecology  
5/2017 - 4/2020 Co-Director  
Translational Research in Ovarian Cancer Laboratories (TROC  
Labs)  
5/2017 - 4/2020 Member  
The Institute for Reproduction and Perinatal Research  
5/2017 - 4/2020 Co-Leader, Gynecologic Disease Working Group  
Kansas University Cancer Center  
2/2018-4/2020 Founding Fellowship Director  
Gynecologic Oncology Fellowship  
10/2018-4/2020 Vice Chair for Research  
Department of Obstetrics and Gynecology  
4/2019 - 4/2020 Diversity and Inclusion Committee  
Department of Obstetrics and Gynecology

WashU Medicine, St. Louis, MO

6/2020 - present Mitchell & Elaine Yanow Professor and Head  
Department of Obstetrics and Gynecology  
6/2020 - present Professor, Secondary Appointment  
Department of Biochemistry and Molecular Biophysics

**Employment History:**

6/1989 - 8/1990 Health Educator  
Student Health Services  
Columbia College, Columbia University  
New York, NY  
1993 - 2005 Co-Owner  
Sugar Hill Real Estate Group  
Harlem, NY

2001 - 2005            Co-Owner  
                              Sugar Hill Bistro  
                              Harlem, NY

## **University, School of Medicine, and Hospital Appointments**

### **Albert Einstein College of Medicine, Bronx, NY**

7/1998 - 6/2004      Attending Staff Physician  
                              Weiler Hospital  
7/1998 - 6/2004      Attending Staff Physician  
                              Montefiore Medical Center  
7/1998 - 6/2004      Attending Staff Physician  
                              Jacobi Medical Center  
7/1998 - 6/2004      Attending Staff Physician  
                              North Central Bronx Hospital  
7/1998 - 6/2004      Attending Staff Physician  
                              Bronx Lebanon Hospital

### **Meharry Medical College, Nashville, TN**

8/2004 - 12/2009     Attending Staff Physician  
                              Nashville General Hospital  
11/2006 - 12/2009    Attending Staff Physician  
                              St. Thomas Hospital  
11/2006 - 12/2009    Attending Staff Physician  
                              Baptist Hospital  
11/2006 - 12/2009    Attending Staff Physician  
                              Centennial Hospital  
11/2006 - 12/2009    Attending Staff Physician  
                              Middle Tennessee Medical Center  
                              Murfreesboro, TN

### **Vanderbilt University, Nashville, TN**

7/2005 - 3/2017      Attending Staff Physician  
                              Vanderbilt University Hospital

### **The University of Kansas School of Medicine, Kansas City, KS**

5/2017 - 4/2020      Medical Director  
                              Gynecologic Oncology Service Line  
                              The University of Kansas Hospital System and the University of  
                              Kansas Cancer Center  
10/2018 - 4/2020      Co-Leader  
                              The Women's Cancer Center  
                              The University of Kansas Hospital System and the University of  
                              Kansas Cancer Center  
4/2019 - 4/2020      Co-Founder  
                              Hereditary Breast and Gynecologic Multi-Disciplinary Program

The University of Kansas Hospital System and the University of  
Kansas Cancer Center

WashU Medicine, St. Louis, MO

06/2020 - present	Chief Obstetrics and Gynecology Barnes-Jewish Hospital
06/2020 - present	Chief Obstetrics and Gynecology St. Louis Children's Hospital
06/2020 - present	Attending Staff Physician St. Louis Children's Hospital
06/2020 - present	Attending Staff Physician Missouri Baptist Medical Center
2022-present	Member, Senior Leadership Committee Siteman Cancer Center

**Professional Licensures and Certifications**

Licenses

3/1995 - 3/2025	New York, inactive
9/2004 – 4/2020	Tennessee, inactive
3/2017 - 7/2026	Kansas, inactive
3/2017 - 1/2027	2017007971, Missouri, active
11/2022-7/2026	036.162929 Illinois, active

Certifications

1/2005	American Board of Obstetrics and Gynecology
2005	Fellow, American College of Obstetricians & Gynecologists
4/2007	American Board of Obstetrics and Gynecology, Subspecialty Gynecologic Oncology
2008	Fellow, American College of Surgeons

Professional Development

1999	The Berlex Oncology Foundation, Clinical Pharmacology of Anticancer Drugs
2001	AACR/ASCO Methods in Clinical Cancer Research
2001	The Berlex Oncology Foundation, Genetics in Oncology Workshop
2003	The Berlex Foundation, Faculty Development Course
2005 - 2006	Joy McCann Junior Faculty Development for Women in Medicine at Meharry Medical College, Nashville, TN
2006	AAMC, Early Career Women Faculty Professional Development Program
2008 - 2017	Women on Track, Vanderbilt University Medical Center, Nashville, TN

2009	daVinci Gynecologic Surgery Training Program (ArnoldAdvincula, MD)
2010 - 2017	Newman Society, Vanderbilt University, Nashville, TN
2018	Quality Academy, The University of Kansas Hospital System, Kansas City, KS
2018 - 2019	APGO/CREOG Program Director School
2022	Harvard T. H. Chan School of Public Health, Program for Chairs of Clinical Services Leadership Course, Boston MA
2023	CUCOG, The Council of University Chairs of Obstetrics and Gynecology, 2023 Chairs Course, Baltimore MA

### **Honors and Awards**

1991	NIH/Dean's Fellowship for Research
1992	Metropolitan Life Foundation Award
1992	National Medical Fellowships
1992 - 1994	Malcolm X Scholarship
1992 - 1994	John Bohmfalk Scholarship
7/1993 - 8/1993	Minority Faculty Development Visiting Clerkship Program, Harvard Medical School
1994	Aaron Diamond Award in Human Rights and Medicine Externship in Malawi and Mozambique
1994	Dr. Cecil G. Marquez/B.A.L.S.O. Student Award for Excellence Gate Pharmaceutical Achievement Award in Obstetrics & Gynecology
2000 - 2006	Reproductive Scientist, Development Program Award APGO/CREOG-NICHD Scholar (2000-2002) NIH Scholar (2002-2003) Ovarian Cancer Research Fund Scholar (2003-2006)
2003 - 2008	Harold Amos Medical Faculty Development Program Scholar Robert Wood Johnson Foundation
2004	Distinguished Faculty Mentor Recognition Award, Hispanic Center of Excellence Albert Einstein College of Medicine
2004	Leo M. Davidoff Society, Outstanding Achievement Award in Teaching Albert Einstein College of Medicine Special Awards or Recognition for Professional Activity
2014, 2015	Five Star Customer Service Award, Vanderbilt Medical Group
2018	Ovarcome Heroes Award
2018	Inducted Member, the American Gynecological and Obstetrical Society (AGOS)
2019	Inducted Member, the American Society of Clinical Investigation (ASCI)
2021	Inducted Member Alpha Omega Alpha Honor Medical Society (AOA), Class of 2021
2021 - 2025	Castle Connolly, Top Doctors, St. Louis
2022	President's Achievement Award, Society of Reproductive Investigation

2023 President's Award, Society of Gynecologic Oncology  
2024 Inducted Member, the Association of American Physicians (AAP)

## **Editorial and Review Responsibilities**

### Editorial Positions

2022 - 2025 Associate Editor, Elsevier Gynecologic Oncology

### Ad Hoc Manuscript Reviews (Selected)

Annals of Surgical Oncology

BMC Cancer

Cancers

Cancer Prevention Research

Cancer Research

Chemotherapy

Clinical Cancer Research

Frontiers Oncology, Genome Medicine

Gynecologic Oncology

Journal of the American Medical Association (JAMA)

JAMA Oncology

Journal of the National Medical Association

Molecular Cancer Research

Neoplasia

Oncotarget

PLoS One

PLoS Medicine

### Extramural Grant Review

2006 - 2007 National Institutes of Health: Special Emphasis Panel Study Section

2012 - 2013 Department of Defense Ovarian Cancer Program

2013 - 2014 National Institutes of Health: Special Emphasis Panel Study Section

2014 - 2015 National Institutes of Health: Molecular and Integrative Signal Transduction (MIST) Study Section, Reducing Health Disparity Study Section, SBIR Study Section, National Institute of Biomedical Imaging and Bioengineering, National Institute on Minority Health and Health Disparities (U54) Hearing the Ovarian Cancer Whisper (HOW) Foundation

2015 - 2021 National Institutes of Health: MIST Study Section, Permanent Member (2015-2021), Specialized Programs of Research Excellence (SPORE) Study Section, Special Emphasis Panel Study Sections

2015 - present Ovarian Cancer Research Fund/Ovarian Cancer Research Alliance  
2018 Florida Department of Health, James, and Esther King Research Program

	Meharry Medical College, External Grant Reviewer for U54 Program
2018 - 2022	Foundation for Women's Cancer Research Committee
2023-2025	NIH: Frederick National Laboratory Advisory Committee (FNLAC)/NCI, Review of NCI Intramural Research programs
2024 – present	NIH: National Institute of Environmental Health Sciences (NIEHS) Board of Scientific Counselors (BSC)
2025	R03R21 Co-Chair, Special Emphasis Study Section, NCI/NIH

## **Community Service Contributions**

### WashU Medicine (WUSM)/Barnes Jewish Hospital (BJH) Committee and Administrative Service:

2020 - 2021	Joint Incident Command Center Leadership for COVID-19 Response, BJH
2020 - present	Member, Washington University School of Medicine – Executive Faculty
2020 - present	BJH Medical Executive Committee
2020 - present	Women and Infants Executive Committee, Barnes Jewish Hospital and St. Louis Children's Hospital, St. Louis, MO
2020 - present	WUSM Administration and Finance Committee
2020 - present	Faculty Practice Plan (FPP) Clinical Practice Committee, WUSM
2020 - present	FPP Professional Liability Committee
2020 - 2024	FPP Clinical Program Development (CPD) Fund Committee
2021-present	WUSM Member and Chair, Ad Hoc Promotion Committees
2021	WUSM Accreditation 2023, LCME Subcommittee, Educational Program leading to the MD Degree Part 2 Task Force Subcommittee
2021-present	Center for the Study of Race, Ethnicity & Equity (CRE2) Faculty Affiliate
2021- present	WUSM PDAC SPORE Internal Advisory Board
2021 - present	Member, Division of Biology & Biomedical Sciences (DBBS),
2021 - present	Co-Chair, Institute of Clinical and Translational Sciences (ICTS), Internal Advisory Committee (IAC)
2021 - present	Member, Intellectual and Developmental Disabilities Research Center (IDDRC), Committee of Institutional Advisors
2021 - present	WUSM Member of Neurology Chair Search
	WUSM Member of Surgery Chair Search
2021 - present	Siteman Cancer Center Senior Leadership Committee, BJH
2021 - present	BJH Medical Staff Bylaws Committee
2021 - 2022	WUSM Member of Educational Program Leading to the MD Degree Part 2 Task Force Subcommittee for the Liaison Committee on Medical Education (LCME) Self Study Task Force
2022	Bill Danforth/Washington U Physician-Scientist Initiative Committee

Internal Advisory Board for Department of Pediatrics Child Health Research Center (NICHD K12) and Physician-Scientist T32 programs  
WUSM Governance Committee  
Member, Chair of Radiology Search Committee  
Co-Chair, Task Force on Climate & Culture  
2023 Member, Internal Advisory Board for NCI application multi cancer screening/detection test  
Member, Co-Chair of Radiation Oncology Search Committee  
Interdisciplinary Consulting Committee - Dean, School of Public Health  
2024 - 2026 Vice Chair, Academic Affairs Committee, WUSM  
2025 Women's and Infants Service Line, St. Louis Children's Hospital  
2026-2028 Chair, Academic Affairs Committee, WUSM

Other University Committee, Hospital and Administrative Service:

Albert Einstein College of Medicine, Bronx, NY

1997 - 1998 Resident Representative, The New York Hospital Quality Assessment, and Improvement Committee  
The New York Presbyterian Hospital, New York, NY  
1997 - 1998 Resident Representative, Quality Assurance Committee  
Department of Obstetrics and Gynecology Weill-Cornell  
Albert Einstein College of Medicine  
University Medical Center, New York, NY  
2003 - 2004 Member, Quality Improvement Committee  
Department of Obstetrics & Gynecology and Women's Health,  
Albert Einstein College of Medicine & Montefiore Medical  
Center, Bronx, NY

Meharry Medical College, Nashville, TN

2004 - 2008 Member, Quality Assurance Committee  
Department of Obstetrics & Gynecology  
2004 - 2008 Member, Cancer Committee and Tumor Board  
Nashville General Hospital at Meharry Medical College  
2005 - 2007 Member, Faculty Senate  
2006 - 2008 Member, Department of Obstetrics & Gynecology Executive  
Faculty Committee  
Member, Department of Obstetrics & Gynecology Finance  
Committee  
Member, Department of Obstetrics & Gynecology Education  
Committee  
2006 - 2008 Member, Operative and Other Invasive Procedures Committee,  
Nashville General Hospital at Meharry  
2007 Member, Search Committee  
Director of the Center for Molecular and Behavioral Neuroscience

2022-present Member, Research Committee  
Presidential Transition Team  
Member, Technology Policy, and Intellectual Transfer Committee  
External Advisory Committee (EAC) for Meharry's RCMI Health  
Disparities Research Center

Vanderbilt University, Nashville, TN

2008 - 2017 Member, Multidisciplinary Tumor Conference, Department of  
Obstetrics & Gynecology  
2011 - 2014 Member, Cancer Health Disparities Task Force  
Vanderbilt-Ingram Cancer Center  
2011 - 2017 Member, Departmental Research Committee, Department of  
Obstetrics & Gynecology  
Chair, Departmental Research Infrastructure Sub-Committee,  
Department of Obstetrics & Gynecology  
Supervisor, Research Support Staff, Department of Obstetrics &  
Gynecology  
Liaison to Office of Diversity, Department Obstetrics &  
Gynecology  
2014 - 2017 Member, Cancer Health Equity Working Group,  
Vanderbilt-Ingram Cancer Center  
Member, HPV Working Group  
2016 - 2017 Member, Academic Integration Metrics Task Force

The University of Kansas School of Medicine, Kansas City, KS

2017 - 2020 Member, Cancer Health Equity Working Group  
Member, HPV Working Group  
Kansas City Cancer Center  
2018 - 2020 Member, Executive Dean Search Committee  
Member, Executive Committee, Department of Obstetrics  
Gynecology  
Member, Promotion and Tenure Committee, Department of  
Obstetrics & Gynecology  
Member, Research Committee, Department of Obstetrics  
Gynecology  
2017 - 2020 Member, Oncology Service Line Committee  
The University of Kansas Hospital System and the University of  
Kansas Cancer Center  
2019 - 2020 Member, Chair of Pathology Search Committee  
2019 - 2020 Member, Cancer Committee  
The University of Kansas Hospital System and the University of  
Kansas Cancer Center

Community Outreach & Volunteer Service:

Nashville, TN

2005 - 2015 Member, National Black Leadership Initiative on Cancer III

2005 - 2017 Physician Volunteer and Advocate  
American Cancer Society

2006 - 2010 Member, Advisory Board  
The Witness Project® of Nashville

2006 - 2008 Chair, Vaccine Delivery and Financing Working Group  
Cervical Cancer Elimination Committee (Governor-Appointed Task Force)

2006 - 2010 Member, Hadley Park Junior Tennis Development Program

2008 - 2012 Member, Advisory Board  
Susan G. Komen for the Cure  
Nashville Affiliate

2014 - 2014 Cervical Cancer Free

2015 - 2017 Member, Health and Human Services Committee  
The Nashville Chapter of the Links, Inc.

*Kansas City, KS*

2017 - 2022 Member, National Trends and Services Committee  
The Greater Kansas City Chapter of the Links, Inc.

2017 - 2022 Member, Health and Human Services Committee  
The Greater Kansas City Chapter of the Links, Inc.

2017 - 2022 Member  
Scholarship Committee  
The Greater Kansas City Chapter of the Links, Inc.

*St. Louis, MO*

2022 - present Member, Health and Human Services Committee  
The St. Louis (MO) Chapter of the Links, Inc.

2025-present Chair, Nomination Committee

Membership in Professional Societies

Fellow, American College of Obstetricians and Gynecologists  
Fellow, American College of Surgeons  
Fellow, American Gynecological and Obstetrical Society  
American Association for Cancer Research  
Alpha Omega Alpha  
American Society of Clinical Oncology  
American Society of Clinical Investigation  
Association of American Physicians  
National Medical Association  
Ovarian Cancer Committee of the NRG Oncology Gynecologic Oncology Group  
Society of Gynecologic Oncology  
Society of Reproductive Investigation  
Society of Black Academic Surgeons

National Panels, Committees, Boards

*Society of Gynecologic Oncology*

2000 - 2001	Member, Fellows Committee
2008 - 2011	Member, Marketing and Communications Committee
2011 - 2014	Member, Health Disparities Task Force
2020 - 2021	Member, Program Committee, (Annual Meeting 2021)
2020 - 2021	Member, Nominating Committee (Annual Meeting 2021) Program Committee
2022 - 2023	Co-Program Chair (2023 Annual Meeting)

*Reproductive Scientist Development Program*

2000-present	Executive Committee Member
--------------	----------------------------

*Ovarian Cancer National Alliance (OCRA)*

2006 - 2016	Member, Scientific and Medical Advisory Committee
2015 - 2016	Member, Scientific Advisory Committee
2016 - present	Member Scientific and Medical Advisory Committee
2019 - present	Review Chair, Liz Tilberis Mentored Investigator Award

*Society of Black Academic Surgeons*

2016 - present	Member, Research and Education Committee
2018 - 2021	Chair, Health Disparities and Equity Committee
2018 - present	Member, Women in Surgery Committee
2021 - present	Member, Health Disparities and Equity Committee
2022 - 2025	Secretary

*Foundation for Women's Cancer*

2017 - 2022	Member, Research and Awards Committee
-------------	---------------------------------------

*Society of Reproductive Investigation*

2018 - 2022	Program Committee
2018 - 2022	Program Director (Annual Meeting 2022)

*Ovarcome*

2019 - present	Advisory Board
----------------	----------------

*Gynecologic Oncology Group (GOG)/NRG Oncology*

2019 - present	Member, Ovarian Committee
2019 - 2023	Core Voting Member, Ovarian Committee

*American Board of Obstetrics and Gynecology*

2019 - present	Examiner, Subspecialty (Gynecologic Oncology)
2019 - present	Evaluator for Written Examination (Gynecologic Oncology)
2020 - present	Evaluator for Written Examination (Gynecologic Oncology)

*American Board of Gynecology*

2020 - present	Certifying Examination Development Committee (CEDC)
----------------	---

*National Cancer Institute*

2021-2025 Frederick National Laboratory Advisory Committee (FNLAC)

*American Association for Cancer Research (AACR)*

2022 Annual Meeting 2022 Scientific Program Subcommittee – CL07

*Scientific Advisory Board (SAB)*

2022 - 2024 Member, Moon Shots Program M.D. Anderson Cancer Center  
The University of Texas, Houston TX

*AACR-Women in Cancer Research*

2023 - 2024 Member  
2023 - 2026 Council Member

*Dana-Farber/Harvard Cancer Center Endometrial Cancer SPORE*

2024-present External Advisory Board Member

*Dana-Farber/Harvard Cancer Center Endometrial P01*

2024-present Chair, Advisory Board

*NIH: National Institute of Environmental Health Sciences (NIEHS) Board of Scientific Counselors (BSC)*

2024-present Member

*American Cancer Society*

2025-2027 Discovery Scientific Council

**Consulting Relationships and Board Memberships**

2015 Advisory Board  
Genentech  
South San Francisco, CA  
2017 Advisory Board  
Vertex Pharmaceuticals  
Boston, MA  
2019 Speaker's Bureau  
Astra Zeneca  
Gaithersburg, MA and Wilmington, DE  
2024 - 2028 Board Member, Burroughs Wellcome Fund  
Durham, NC  
2025 - 2027 Discovery Scientific Council, American Cancer Society  
Hagerstown, MD

**Teaching**

**Major External Invited Presentations, including Professorships and Lectures**

*National \*Selection from 2020-2025\**

- 1/2020 Speaker, Alaska Cancer Survivor Course, 8th Annual Let Every Woman Know Gynecologic Cancer Arts of Healing Weekend, Becoming a Patient Advocate in Your Own Cancer Journey. Providence Cancer Center Anschutz Medical Campus, Anchorage AK
- 2/2020 Speaker, Alaska Cancer Survivor Course, 8th Annual Let Every Woman Know Gynecologic Cancer Arts of Healing Weekend, Germline & Somatic Genetic Testing: A Guide for Providers. Providence Cancer Center Anschutz Medical Campus, Anchorage AK
- 1/2021 Leadership Moderated Panel Discussion: Leading with purpose in times of disaster and emergency, Society of Maternal-Fetal Medicine 41st Annual Pregnancy Meeting, Virtual
- 3/2021 Speaker, Markey Research Virtual Seminar, University of Kentucky's Markey Cancer Center, Perspectives on Treatment Advances in Ovarian Cancer, University of Kentucky
- 4/2021 Speaker, Virtual Evolution Kansas City Conference, Gyn Treatment/Maintenance (PARP) and PreVivor (Gene Carrier Identified via Cascade Testing), The University of Kansas Cancer Center
- 4/2021 Speaker, Virtual, Vanderbilt University Graduate Program in Cancer Biology, Perspectives on Treatment Advances in Ovarian Cancer. Hosted by Cancer Biology Diversity Equity and Inclusion Committee
- 5/2021 Speaker, Virtual, Distinguished Lecture Fox Chase Cancer Center, Temple Health, Pathobiology of Ovarian Cancer, and Identification of Molecular Targets for Novel therapeutics Strategies
- 7/2021 Co-Moderator, Mini-Symposia: Drivers and Therapeutic Targets for Gynecologic Cancers Associated with Benign Gynecologic Conditions, Society of Reproductive Investigation Annual Scientific Meeting, the Society for Reproductive Investigation, Boston MA
- 9/2021 Speaker, Leading Through Research. Reproductive Scientist Development Program (RSDP) Annual Retreat, Chicago IL
- 9/2021 Speaker, Virtual Grand Rounds, Perspectives on Treatment Advances in Ovarian Cancer, Northwell Health, Department of Obstetrics and Gynecology, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell
- 10/2021 Panelist, Virtual Meeting, Society of Family Planning Annual Meeting, "The legacy of anti-Black racism in obstetrics and gynecology"
- 10/2021 Speaker, Virtual, ACS Clinical Congress, Breaking Barriers: Dr. Dorothy Lavinia Brown, FACS Surgeon, Teacher, and Legislator,
- 11/2021 Speaker, Virtual, Magee-Women's Summit 2021, Breakout Session: The metabolic Underpinnings of Reproductive Disorders

- and Cancer, Magee-Women's Research Institute, University of Pittsburgh
- 11/2021 Speaker, Virtual Live Webinar, Advances and Challenges for Delivering Women's Healthcare in Medical Centers, Omar Pasalodos, M.D. Memorial Lecture, Baptist Health South Florida
- 1/2022 Contributor, CME article AiCME on Racial Disparity in ovarian cancer.
- 3/2022 Women's Leadership Symposium Keynote Speaker, Virtual, 2<sup>nd</sup> Annual (WIAM) Women in Academic Medicine, "Innovate & Revolutionize: First, Not Last" University of Miami Miller School of Medicine
- 3/2022 Virtual Speaker, Grand Rounds, Department of Obstetrics and Gynecology and Women's Health, "Perspectives on Treatment Advances in Ovarian Cancer" Albert Einstein College/Montefiore Medical Center
- 3/2022 Speaker, Virtual Grand Rounds, Perspectives on Treatment Advances in Ovarian Cancer, Department of Obstetrics and Gynecology Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center
- 3/2022 Speaker, Virtual Workshop, Rising Leaders Program at UW School of Public Health, Fireside Chat Department of Obstetrics and Gynecology, University of Washington School of Medicine
- 3/2022 Virtual Speaker, Spotlight on Women in Medicine and Science (SWIMS) Symposium, WashU Medicine
- 3/2022 Moderator, Lunch and Learn Symposium I: How to Build a Successful Research Environment in Reproduction, 69<sup>th</sup> Annual Scientific Meeting, the Society for Reproductive Investigation, Denver CO
- 6/2022 Speaker, American Society of Clinical Oncology (ASCO), Annual Meeting, Searching for the Next Holy Grail in Ovarian Cancer: Emerging Targeted Therapies, Chicago IL
- 8/2022 Speaker, Annual Meeting and Scientific Assembly of the National Medical Association, Session Ovarian Cancer: The Changing Landscape of Diagnosis, Treatment and Long-Term Management, Presentation-We Are OVAR-IT! We Can Improve Ovarian Cancer Outcomes for Black Women, Atlanta GA
- 9/2022 Speaker, Koch Institute Seminar Series: A Physician-Scientist's Perspective on Advances in Ovarian Cancer Treatment, Cambridge MA
- 9/2022 Speaker/Panelist, Promotion and Profess Institute (PPI) during Annual Society of Black Academic Surgeons (SBAS), Session How do you create a successful research funding proposal? How is your Application Reviewed? Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA

- 10/2022 Panel Speaker, Mighty Dream Forum, Equity & Advocacy in Women’s Healthcare, Publicis Health & Publicis Groupe, Norfolk VA
- 1/2023 Virtual Speaker, 11<sup>th</sup> Annual Arts of Healing Cancer Survivor Virtual Conference, Let Every Woman Know (LEWK) – Alaska
- 2/2023 Plenary Panel Session, ACGME Annual Education Conference, Dobbs and the Future of Graduate Medical Education, Nashville TN
- 3/2023 Virtual Speaker, OVARCOME, Zeal for Teal Survivorship Empowerment Series, Advances in Ovarian Cancer Treatment: Where Are We Headed?
- 5/2023 Keynote Speaker, OHSU Resident Research Day, A Physician-Scientist’s Perspective on Advances in Ovarian Cancer Treatment, Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland OR
- 8/2023 Keynote Speaker, 10<sup>th</sup> Annual Health Disparities Symposium, Birth Equity, Changing the Narrative: From Justice to Joy, SSM Health St. Mary’s Hospital, National Association of Health Services Executives St. Louis Chapter, St. Louis MO
- 9/2023 Keynote Speaker, Meharry Research Week, Office of Medical Student Research, WUSM Meharry Summer Research Program (Meharry SRP) Meharry Medical College, Nashville TN
- 10/2023 Speaker, Leadership Development for Physicians in Academic Health Centers, Harvard T. H. Chan School of Public Health, “The Physician as Leader”, Boston MA
- 11/2023 Virtual Speaker, Ovarian Cancer National Conference, Ovarian Cancer Research Alliance (OCRA)
- 2/2024 Virtual Speaker, Scientific Speaker Series, Ovarian Cancer: Moving to a Personalized Treatment Approach, Office of Women’s Health, U.S. Food and Drug Administration
- 2/2024 Virtual Guest Commentator, Understanding Gynecologic Cancers in Vulnerable Communities, Albany Medical College
- 2/2024 Guest Commentator, Understanding Gynecologic Cancers in Vulnerable Communities, Online Community Grand Rounds, Albany Medical College
- 3/2024 Speaker, DNA Damage, Mutation and Cancer, Gordon Research Conference (GRC), Ventura CA
- 4/2024 Virtual Speaker, Siteman’s Program to Enhance Diversity (PED), with the Missouri Louis Stokes Alliance for Minority Participation (MOLSAMP), Women’s Health in Cancer Research: Below the Belt’ gynecologic cancer disparities.
- 4/2024 Co-Chair, AACR Professional Advancement, Building an Effective Mentorship Team: Essential Strategies at Every Stage in Your Career,” AACR Annual Meeting 2024, San Diego CA

- 4/2024 Grand Rounds Speaker, Targeting DNA Damage Repair with Epigenetic Drugs in Ovarian Cancer, Indiana University Comprehensive Cancer Center (IUSCCC), Indianapolis IN
- 6/2024 Speaker, Endometrial Cancer Inequities: A Call to Action, 35<sup>th</sup> Annual James Symposium, Meharry Medical College, Nashville TN
- 12/2024 Speaker, A Surgeon-Scientist's Perspective on Ovarian Cancer Care and Research. Medical Oncology Grand Rounds, University of Missouri, Columbia MO
- 11/2025 Speaker, Session 3- Translating Innovation to the Clinic: Personal Perspectives on Advances in Ovarian Cancer Care and Research, Ovarian Cancer Midwest Focus Conference (OCMF), Minneapolis, Minnesota
- 12/2025 Keystone Health Equity Panelist, Regenerative Biology of the Female Reproductive System: Advances and Applications, Keystone Symposia, Tupper Manor at Endicott College, Beverly MA
- 2/2026 Panel Speaker, Leading through Chaos...Keeping Research Alive in Uncertain Times, CUCOG, The Council of Chairs of Obstetrics and Gynecology, Seattle, Washington.

*International*

- 10/2009 Speaker, A No-Cost Breast Cancer Screening Program Promotes Cervical Cancer Screening Services to an Underserved Population of Women. Bi-annual Meeting of the International Federation of Gynecology and Obstetrics (FIGO). Cape Town, South Africa
- 7/2013 Speaker, An Update on New Cervical Cancer Screening Guidelines. Obstetrics and Gynecology Section, Annual Meeting of the National Medical Association. Toronto, Canada
- 3/2016 Speaker, Personalized Epigenetic Drug Therapy in Ovarian Cancer, Annual Meeting of the Society of Reproductive Investigation, Montreal, Canada
- 3/2019 Moderator, Lunch and Learn Symposium I: Insights Into Drug Discovery and Development in Women's Health: From Target Ideas to Molecules, to Medicine, 66<sup>th</sup> Annual Scientific Meeting, the Society for Reproductive Investigation, Paris, France

WashU Presentations & Lectures

- 9/2020 Speaker, Camel Lectureship: Perspectives on Treatment Advances in Ovarian Cancer
- 10/2020 Speaker, Center for Cardiovascular Research 2020-2021 Seminar Series, Perspectives on Treatment Advances in Ovarian Cancer
- 2/2021 Speaker, CRepHS Seminar Series, Targeting Macrophages in Ovarian Cancer
- 5/2021 Speaker, Virtual Grand Rounds, Perspectives on Treatment Advances in Ovarian Cancer, Department of Internal Medicine

11/2021	Speaker, Virtual Grand Rounds Neurosurgery, Perspectives on Treatment Advances in Ovarian Cancer, Department of Neurosurgery
12/2021	Speaker, American Medical Women's Association (AMWA) Mentorship Small Breakfast Series
12/2021	Keynote Speaker, Cancer Research Symposium, "It's always a good time to take charge of your career"
4/2022	Speaker, K12 Oncology "Luncheon with the Leaders Seminar"
7/2022	Speaker, Department of Anesthesiology Grand Rounds, We are OVAR-IT! Inequities in Ovarian Cancer Outcomes among Black Women.
10/2022	Speaker, Research Paths in OBGYN, Professional Development Series
2/2023	Panelist, Symposium on the Race and Medicine in St. Louis Past to Future, Clark-Fox Forum
11/2023	Speaker, School of Medicine, Medical Advancement's EUREKA! Science Social
2/2024	Speaker, Part II The Politics of Reproduction Course, Gynecologic Oncology, and work as OB/Gyn Chair, Department of African & African American Studies
4/2024	Speaker, Leading from Where We Are, 3 <sup>rd</sup> Annual Department of Medicine Women in Medicine & Science Seminar (WIMS)
4/2024	Speaker, Targeting DNA Damage Repair with Epigenetic Drugs in Ovarian Cancer, MEDA & WUSTL BPA, Joint Career Development Seminar Series
6/2024	Keynote Speaker, 2024 Washington University Juneteenth Celebration, Significance of Holiday, and work as an advocate for Black women and maternal health.
7/2024	Speaker, WUSM MSTP Historical Lecture
10/2024	Keynote Speaker, 2024 White Coat Ceremony
1/2026	Speaker, CRepHS Seminar Series, Title: Epigenetic strategies to overcome chemotherapy resistance in ovarian cancer
2/2026	Speaker, GYN Cancers Research Meeting, Title: Epigenetic strategies to overcome chemotherapy resistance in ovarian cancer, Radiation Oncology, WashU Medicine

Internal Presentations & Lectures at University [e.g., previous places of employment]:

*Albert Einstein College of Medicine, Bronx, NY*

2001 – 2004	Obstetrics & Gynecology, Gynecologic Oncology Rotation Lecturer and Clinical Preceptor for medical students, residents, and fellows.
2002 – 2004	Unit 3: "Growth Control and Cancer Molecular and Cellular Foundations of Medicine." Lecturer for 1 <sup>st</sup> year medical students

2003 – 2004 Unit 3: “Growth Control and Cancer Molecular and Cellular Foundations of Medicine.” Course Director, for 1<sup>st</sup> year medical students.

Meharry Medical College, Nashville, TN

2004 – 2008 Obstetrics & Gynecology Clerkship, Gynecologic Oncology Rotation Lecturer and Clinical Preceptor for medical students and residents.

2004 – 2008 Molecular Cell Biology and Genetics II. Lecturer for 1st year medical students.

2008 – 2017 Research Preceptor for medical and graduate rotating students

2008 – 2017 Cancer Biology I and II. Lecturer for graduate students.

Vanderbilt University, Nashville, TN

2005 – 2016 Cancer Biology I. Lecturer for graduate students.

2008 – 2017 Research Preceptor for medical and graduate rotating students

Belmont University School of Pharmacy, Nashville, TN

2010 – 2017 Guest Lecturer

The University of Kansas Medical Center, Kansas City, KS

2018 – 2020 Cancer Biology. Seminar Leader for graduate students.

2018 – 2020 Didactic Lecturer for medical students and residents.

Clinical Teaching

2001 – 2004 Gynecologic Oncologist at Jacobi Medical Center  
Supervised Medical Students and Residents

2004 – 2008 Sole Gynecologic Oncologist at Nashville General Hospital  
Supervised Medical Students and Residents, Meharry Medical College

2008 – 2017 Bedside Medical Student/Resident Teaching Rounds at Vanderbilt University Hospital (2 hours/week)

2008 – 2017 Intraoperative/Surgical Medical Student/Resident Training (one day/week)

2008 – 2017 Boards review and mock oral examinations at Meharry Medical College and Vanderbilt University (yearly)

2008 – 2013 Multi-disciplinary Tumor Board, Vanderbilt University, Resident Mentor, (2015 – 2017 2 hours/week)

2012 – 2013 Continuing Medical Education (CME) on Screening Guidelines and Primary Prevention of Cervical Cancer to local community hospitals through the Vanderbilt Outreach Program, The University of Kansas Medical Center

2017 – 2020 Bedside Medical Student/Resident Teaching Rounds at the Kansas University Hospital (2 hours/week)

	Medical Student/Resident Rotation at the Kansas University Cancer Center Clinic (8 hours/month)
2018	Robotic simulation for residents (4 hours/year)
2018 – 2020	Operating room simulation and team training design and analysis for residents, faculty, and staff (2 hours/quarter)
2019 – 2020	Supervise Gynecologic Oncology Fellow in Research (2 hours/week)
2020 – present	WashU Fellow’s Clinic, once a month (4 hour/1 month)
2020 – present	Didactic Lecturer for medical students, residents and fellows, WashU Medicine
2020 – present	WashU Medical Student/Resident Rotation (4 hour/1month)
2021 – present	Gynecologic Oncology Fellow (2-8 hours/month)

Graduate Student Teaching

Qualifying Examination Committee Member

*Meharry Medical College, Nashville, TN*

2006 – 2008	Christy Marrs, PhD Candidate, Cancer Biology
2007 – 2008	Charmaine O’Brien, PhD Candidate Cancer Biology Vanderbilt University, Nashville TN
2010	Shenika Poindexter, PhD Candidate, Cancer Biology
2012	Charnise Gooding, PhD Candidate, Cancer Biology
2012 – 2013	Jennifer Malinowski, PhD Candidate, Center for Human Genetics Research
2013	Keisha Nicole Hardeman, PhD Candidate, Cancer Biology
2015	Michael Bray, PhD Candidate, Cancer Biology

Thesis Committee Member

*Vanderbilt University, Nashville TN*

2012 – 2013	Elizabeth Vargis, PhD, Biomedical Engineering
2013 – 2016	Katherine Venmar, PhD Candidate, Cancer Biology
2014 – 2016	David Austin, PhD Candidate, Cancer Biology
2014 – 2017	Christine O’Brien, PhD Candidate, Biomedical Engineering
2015 – 2017	Michael Bray, PhD Candidate, Human Genetics Program
2016 – 2017	Keisha Nicole Hardeman, PhD Candidate, Cancer Biology

*The University of Kansas Medical Center, Kansas City KS*

2019	David Standing, PhD Candidate, Cancer Biology External Thesis Examiner (International)
2018-2020	Masters (MSCI) Thesis Committee, Shariska Peterson,

*International*

2013	Bee Shin Tan, PhD Candidate University of Melbourne, Australia
2017	Janson Tse, PhD Candidate La Trobe School of Cancer Medicine, Melbourne, Australia

## **Mentorship & Sponsorship Record**

### a) Undergraduate Students

2011-2012	Maggie Williams, Vanderbilt University, Nashville TN Tiffany Edwards, Vanderbilt University, Nashville TN Marcella Riley, Fisk University, Vanderbilt University, Nashville TN
2012	Jade Readus, Tennessee State University, Nashville TN
2012 – 2013	Michelle Park, Vanderbilt University, Nashville TN
2012 – 2014	Anum Lalani, Vanderbilt University, Nashville TN
2015	Alexandra Steck, Smith College, Northampton MA
2016	Toby Barrack, Vanderbilt University, Nashville TN
2016	Abdirahman Osman, Tennessee State University, Nashville TN

### b) Medical Students

2010 – 2011	Annie Y. Liu, BS, Vanderbilt University, Nashville TN
2011 – 2012	Carmen Adams, BA, Vanderbilt University, Nashville TN
2012	Oluwafunmilayo B. Adebayo, BS, Meharry Medical College, Nashville TN
2012	Lanzi Sinaise, BS, Meharry Medical College, Nashville TN
2013 – 2016	Dembi Huya-Kouadio, MS, Meharry Medical College, Nashville TN
2014	Stacey Smith, MS, Meharry Medical College, Nashville TN
2015	LeShaun Clayton, BS, Meharry Medical College, Nashville TN
2015 – 2017	Kofi Sarfo-Kantanka, MS, Meharry Medical College, Nashville TN Alexandra Foxx, BA, Vanderbilt University, Nashville TN Gabriella Cozzi, BS, Vanderbilt University, Nashville TN
2016	Janese Thompson, BA, Meharry Medical College, Nashville TN

### c) Residents

2012 – 2013	Andres Ayuso, MD, Obstetrics and Gynecology, Vanderbilt University, Nashville TN
2013 – 2015	Amy Zhai, MD, Obstetrics and Gynecology, Vanderbilt University, Nashville TN
2014 – 2017	Tara Nielsen, DO, Obstetrics and Gynecology, Vanderbilt University, Nashville TN
2015 – 2017	Emad Elsamadicy, MD, Obstetrics and Gynecology, Vanderbilt University, Nashville TN
2016 – 2017	Sumit T. Mehta, MD, Obstetrics and Gynecology, Vanderbilt University, Nashville TN

d) Postdoctoral fellows

- 2005 – 2007 Brenda Green-Jarvis, PhD, Post-doctoral Fellow, Cancer Biology, Meharry Medical College, Nashville TN
- 2006 – 2007 Tracy Miller-Torbett, PhD, Post-doctoral Fellow, Cancer Imaging, Vanderbilt University, Nashville TN
- 2007 – 2010 Hye-Joeng Lee, PhD, Post-doctoral Fellow, Cancer Imaging, Vanderbilt University, Nashville TN
- 2012 – 2013 Syeda S. Zaidi, MD, Clinical Fellow, Endocrinology, Internal Medicine, Vanderbilt University, Nashville TN
- 2018 – 2019 Shariska Petersen, MD, Post-doctoral Fellow, Gynecologic Oncology, The University of Kansas Medical Center, Kansas City KS
- 2021 – 2024 Tyler Woodard, MD, Obstetrics and Gynecology, Washington University, St. Louis MO

e) Graduate Students

- 2007 – 2013 Elizabeth Vargis, BS, Biological Engineering, Vanderbilt University, Nashville TN
- 2011 – 2012 Erica Wass, BS, Pharmacy Student, Belmont School of Pharmacy, Nashville TN

f) Other learners

- 2013 – 2014 Amna Asad, High School Student, STEM Program, Harpeth Hall School, Nashville TN

g) Faculty Mentees

- 2005 – 2008 Deok-Soo Son, DVM, Assistant Professor, Obstetrics and Gynecology, Meharry Medical College, Nashville TN
- 2008 – 2017 Andrew Wilson, PhD, Research Assistant Professor, Obstetrics and Gynecology, Vanderbilt University, Nashville TN
- 2012 – 2017 Alicia Beeghly-Fadiel, PhD, Assistant Professor, Epidemiology, Vanderbilt University Nashville TN
- 2017 – 2020 Andrea D. Jewell, MD Assistant Professor, Obstetrics and Gynecology, The University of Kansas Medical School, Kansas City KS
- Lori A. Spoozak, MD, Assistant Professor, Obstetrics and Gynecology, The University of Kansas Medical School, Kansas City KS
- 2020 – present Mary M. Mullen, MD, Assistant Professor, Obstetrics and Gynecology, WashU Medicine, St. Louis MO
- Whitney Ross, MD, Assistant Professor, Obstetrics and Gynecology, WashU Medicine, St. Louis MO
- Priyanka Verma, PhD, Assistant Professor, Internal Medicine, WashU Medicine, St. Louis MO

John Kraus, PhD, Assistant Professor, Internal Medicine,  
WashU Medicine, St. Louis MO

h) Mentoring programs

- 2014 Conquer Cancer Foundation of ASCO 2014 Medical Student Rotation Mentor for Dembi Huya-Kouadio, Meharry Medical College student
- 2014 – 2015 ASCO Diversity Mentoring Program Mentor for Danielle O. Wright, Medical University of South Carolina student, (1 hour/month)
- 2001 – present Informal mentor for high school, undergraduate, graduate students, medical students, and faculty with interests in women's cancer, cancer disparities, and biomedical sciences (4 hours/month)

**Research**

Present Extramural Grants:

- 1) R01CA243511 (PI: Khabele) 03/02/2020-02/28/2026  
NIH/NCI \$2,336,501  
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer  
Role: PI
- 2) K12CA167540 (PI: Govindan/DiPersio) 05/05/2022-03/31/2027  
NIH/NCI \$4,050,000  
Washington University Paul Calabresi Career Development Award for Clinical Oncology (K12)  
Role: Associate Program Director
- 3) HT9425-23-1-0133 (PI: Verma) 09/01/2023-08/31/2027  
Dept. of Defense \$1,127,375  
Replication-driven Vulnerabilities in Cyclin E1-high Ovarian Cancers  
Role: Co-Investigator
- 4) P50CA265793 (PI: Mutch/Leslie/Benbrook) 08/23/2023-07/31/2028  
NIH/NCI \$778,642  
Route 66 Endometrial Cancer SPORE; Developmental Research Program  
Role: Program Director
- 5) K12HD19716 (PI: Khabele/England) 08/01/2025-06/30/2030  
NIH/NICHD \$1,700,115  
WashU-WRHR; Gateway to Improving Women's Reproductive Health  
Role: PI

Present Intramural Grants:

- 1) Barnes Jewish Hospital Foundation (PI: Khabele) 2021-Present  
Koven Wasserman Research Fund

Role: PI

- 2) Barnes Jewish Hospital Foundation (PI: Khabele) 2021-Present  
Rothman House Staff Award  
Role: PI
- 3) Barnes Jewish Hospital Foundation (PI: Khabele) 2022-Present  
Gynecologic Oncology Tissue Bank  
Role: PI
- 4) Barnes Jewish Hospital Foundation (PI: Khabele) 2025-Present  
The Ira C. Gall MD and Judith Gall Award  
Role: PI

Past Extramural Funding:

- 1) G2 RR 03032, (PI: Townsel) 2005 – 2008  
NIH/RCMI  
Dissecting COX-1 related gene pathways in ovarian cancers.  
Mentor: Sudhansu K. Dey, PhD  
Role: PI of pilot project
- 2) U54 CA091405 (PI: Moses) 2006 – 2009  
NIH/NCI  
MMC and VICC: Partners in Eliminating Cancer Disparities COX-1 and HDAC  
inhibitors suppress ovarian cancer growth in vitro and in vivo.  
Role: Co-investigator of pilot project
- 3) R01 CA095405 (PI: Mahadevan-Jansen) 2007 – 2009  
NIH/NCI  
Diagnosis of Cervical Precancers Using Raman Spectroscopy  
Role: Co-investigator
- 4) U54 CA091408 (PI: Moses) 2008 – 2009  
NIH/NCI  
MMC and VICC: Partners in Eliminating Cancer Disparities  
Increasing HPV Vaccine Utilization among Hispanic Girls to Reduce Cervical Cancer  
Disparities  
Role: Co-investigator
- 5) 5 P30 CA068485 (PI: Pietenpol) 2008 – 2010  
NIH/NCI  
Cancer Center Support Grant – start-up funds  
Role: Recipient
- 6) K08CA148887 (PI: Khabele) 2010 – 2015  
NIH/NCI

Targeting Histone Deacetylases with Small Molecule Inhibitors in Ovarian Cancer  
Role: PI

- 7) DOD/Ovarian Cancer Research Pilot Award (PI: Beeghly-Fadiel) 2014 – 2016  
Department of Defense  
The Pharmacogenetics Ovarian Cancer Knowledge to Individualize Treatment (POCKIT) Study  
Role: Co-investigator
- 8) P30CA168524 (PI: Jensen) 2017 – 2020  
NIH/NCI  
Cancer Center Support Grant – start-up funds  
Role: Recipient
- 9) R21CA210210 (PI: Khabele) 2017-2020  
NIH/NCI  
Targeting Cyclin E in Ovarian Cancer with Histone Deacetylase Inhibitors  
Role: (PI: Khabele)
- 10) R01 CA214043 (multi-PI: Yull (corresponding)/Giorgio/Khabele) 3/10/2017-2/28/2023  
NIH/NCI \$1,349,664  
Macrophage-based ovarian cancer immunotherapy  
Role: PI (multi-PI)
- 11) R01CA234553 (Sub Award PI: Khabele; PI: Fuh) 9/01/2022 – 12/31/2024  
UCSF/NIH/NCI \$201,958  
Role of the microenvironment in ovarian cancer metastasis  
Role: Co-Investigator

Past Intramural Funding:

- 1) Deciphera Pharmaceuticals (PI: Khabele) 2019-2020  
Preclinical Studies of Rebastinib in Ovarian Cancer  
Role: PI
- 2) Vanderbilt-Incyte Alliance (PI: Wilson) 2017 – 2018  
Targeting DNA repair proficiency in ovarian cancer with bromodomain inhibitors  
Role: Co-investigator
- 3) Vanderbilt-Incyte Alliance (PI: Khabele) 2016 – 2017  
Targeting DNA repair proficiency in ovarian cancer with bromodomain inhibitors.  
Role: PI
- 4) Marsha Rivkin Foundation (PI: Wilson) 2016 – 2017  
Prognostic significance of TR3/NR4A1 expression in ovarian cancer  
Role: Co-investigator

- 5) Women's Final Four Grant/V Foundation (Co-PI: Khabele and Marnett) 2014 – 2015  
Kay Yow Cancer Fund Imaging Ovarian Cancer with Novel Small Molecule Radiotracers of Cyclooxygenase-1  
Role: Co-PI
- 6) Celgene Corporation (PI Khabele) 2011 - 2013  
Orthotopic propagation of primary human ovarian tumors for preclinical investigation of Istodax  
Role: PI
- 7) Gynecologic Cancer Foundation (PI: Khabele) 2009  
Selective Targeting of HDAC3 in Ovarian Cancer  
Role: PI
- 8) Gloucester Pharmaceuticals (PI: Khabele) 2007 – 2008  
FK228 and Taxol in Ovarian Cancer Cells  
Role: PI
- 9) Cytoc Corporation (PI: Khabele) 2006 – 2007  
Identification of cellular markers of cervical neoplasia  
Role: PI
- 10) Gynecologic Cancer Foundation (PI: Daikoku) 2006  
PPAR delta is a downstream target of COX-1 derived prostaglandins in ovarian cancer. Mentor: Sudhansu K. Dey, PhD  
Role: Co-investigator
- 11) AMFDP/ Robert Wood Johnson Foundation (PI: Khabele) 2004 – 2008  
Using TNFalpha gene expression profiles to predict TX-based chemotherapy response  
Mentors: Leonard Augenlicht, PhD and Samuel Adunyah, PhD  
Role: PI
- 12) Reproductive Scientist Development Program (PI: Khabele) 2004 – 2006  
COX-1 Gene Expression and Apoptosis: Profiling Potential Mechanisms of Chemotherapy Resistance in Ovarian Cancer  
(Mentors: Raju Kucherlapati, PhD, Leonard Augenlicht, PhD, and Sudhansu K. Dey, PhD)  
Role: PI
- 13) Reproductive Scientist Development Program (PI: Khabele) 2000 – 2004  
Gene Expression Profiles in Ovarian Cancer  
NICHD (5K12HD0084) Scholar  
(Mentors: Raju Kucherlapati, PhD and Leonard Augenlicht, PhD)  
Role: PI
- 14) Ovarian Cancer Research Fund Grant (PI: Khabele) 1999 – 2001

Patterns of Gene Expression in Ovarian Cancer  
(Mentor: Raju Kucherlapati, PhD)  
Role: PI

Clinical Research

2006 – 2008	Co-investigator, Gynecologic Oncology Group (GOG) trials, Minority-Based Community Clinical Oncology Program Meharry Medical College and Nashville General Hospital, Nashville, TN
2008 – 2017	Co-investigator, NRG Oncology/GOG and investigator-initiated trials, Vanderbilt University, Nashville, TN
2016 – 2017	Principal Investigator, VICCG114124: PET Imaging of Ovarian Carcinoma with 18F-FSPG, Vanderbilt University, Nashville, TN
2017 – 2020	Co-investigator, NRG Oncology/GOG and investigator-initiated trials, Kansas University Cancer Center, Kansas City, KS
6/2020-present	Co-investigator, NRG Oncology/GOG and investigator-initiated trials, NRG Oncology/GOG and investigator-initiated trials, Washington University Medical School and Siteman Cancer Center, St. Louis, MO

Translational Research

7/2008 – 3/2017 Principal Investigator, Director, Gynecologic Oncology Translational Research, Vanderbilt University, Nashville, TN

Program: The Gynecologic Oncology Translational Research Program focused on the development of individualized molecular diagnostics and therapeutics for ovarian cancer and other gynecologic malignancies, based on genetic and epigenetic alterations in DNA damage response, inflammatory, and cell death pathways. We used patient-derived xenografts and genetically engineered and syngeneic mouse models of ovarian cancer to study these pathways and to test novel diagnostics and therapeutics for eventual translation to the clinic. We generated a tissue repository for ovarian cancer and a clinically annotated tumor bank that served as ongoing and valuable resources for translational research. The Khabele laboratory was also the flagship research group and co-founders for the Vanderbilt Ovarian Cancer Alliance (VOCAL) whose mission was to accelerate translational ovarian cancer research and to join with ovarian cancer survivors and advocates to raise awareness about ovarian cancer.

5/2017 – 4/2020 Principal Investigator, Translational Research in Ovarian Cancer Laboratories (TROC Labs), The Kansas University Cancer Center, Kansas City, KS

Program: I co-led the TROC Labs at the University of Kansas which is an interdisciplinary working group of investigators focused on ovarian cancer research. My own laboratory used a bi-directional translational research approach to develop novel epigenetic drug combinations and novel targets in the tumor microenvironment to treat chemotherapy-resistant ovarian cancer. We used state-of-the-art molecular tools to interrogate clinically annotated tissue samples and patient-derived xenograft models, and to generate relevant pre-clinical findings for rapid translation to the clinic.

6/2020 - present      Principal Investigator, Khabele Laboratory, WashU Medicine, St. Louis, MO

Program: Bi-directional translational research approach to develop novel epigenetic drug combinations and novel targets in the tumor microenvironment to treat chemotherapy-resistant ovarian cancer. We use state-of-the-art molecular tools to interrogate clinically annotated tissue samples and patient-derived xenograft models and to generate relevant pre-clinical findings for rapid translation to the clinic.

## **Bibliography**

### **Original, peer reviewed articles in referred journals.**

- 1) Xiao E, Xia L, Shanen D, **Khabele D**, Ferin M. Stimulatory effects of interleukin-induced activation of the hypothalamo-pituitary-adrenal axis on gonadotropin secretion in ovariectomized monkeys replaced with estradiol. *Endocrinology* 1994;135(5):2093-2098. PMID: 7956932
- 2) **Khabele D**, Chasen S. Cardiac tamponade: An unusual presentation of advanced breast cancer in a pregnant woman. *J Reprod Med* 1999;44:989-991. PMID: 10589415
- 3) **Khabele D**, Runowicz CD. Genetic counseling, testing, and screening for breast and ovarian cancer: practical and social considerations. *Curr Women's Health Rep* 2002;2:163-169. PMID: 12099190
- 4) Gross SJ, Ferreira JC, Morrow B, Dar P, Funke B, **Khabele D**, Merkatz I. Gene expression profile of trisomy 21 placentas: A potential approach for designing noninvasive techniques of prenatal diagnosis. *Am J Obstet Gynecol* 2002;187:457-462. PMID: 12193943
- 5) **Khabele D**, Runowicz CD, Fields AL, Anderson PS, Goldberg, GL. Evaluation of low-dose intraperitoneal interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies. *Gynecol Oncol*.89:420-423. PMID: 12798705
- 6) Sood B, Jones J, Gupta S, **Khabele D**, Guha C, Runowicz C, Goldberg G, Fields A, Anderson P, Vikram B. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. *Int J Radiat Oncol Biol Phys* 2003;57:208-16. PMID: 12909235
- 7) Mani S, McDaid H, Hamilton A, Hochster H, Cohen MB, **Khabele D (sic)**, Griffin T, Lebwohl DE, Liebes L, Muggia F, Horwitz SB. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of Epothilone B, in solid tumors. *Clin Cancer Res* 2004;10(4):1289-1298. PMID: 14977827
- 8) Gorelick C, Lopez-Jones M, Goldberg GL, Romney SL, **Khabele D**. Coenzyme Q10 lipid-related gene induction in HeLa cells. *Amer J Obstet Gynecol* 2004;190:1432-4. PMID: 15167860
- 9) **Khabele D**, Lopez-Jones M, Yang W, Arango D, Gross SJ, Augenlicht L, Goldberg G. Tumor Necrosis Factor- $\alpha$  Related Gene Response to Epothilone B. *Gynecol Oncol* 2004;93:19-26. PMID:50472098
- 10) **Khabele D**, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, Montgomery Rice V. Drug-induced inactivation or gene silencing of Class I

- histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. *Cancer Biol Ther* 2007;6:795-801. PMID:17387270
- 11) Son DS, Parl AK, Montgomery Rice V, **Khabele D**. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. *Cancer Biol Ther* 2007;6:1302-1312. PMID:17712227
  - 12) Daikoku T, Tranguch S, Chakrabarty A, Wang D, **Khabele D**, Orsulic S, Morrow JD, DuBois RN, Dey SK. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. *Cancer Res* 2007;67(11):5285-5292. PMID:17545608
  - 13) Lyshchik A, Hobbs SB, Fleischer AC, **Khabele D**, Son DS, Gore JC, Price RR. Ovarian volume measurements in mice with high-resolution ultrasonography. *J Ultrasound Med* 2007;26:1419-1425. PMID:17901144
  - 14) Klugman SD, Gross SJ, **Khabele D**, Liang J, Livne K, Lopez-Jones M, Gross B, Cordero DR, Reznik S. Expression of Keratin 8 and TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Down Syndrome Placentas. *Placenta* 2008;29:382-384. Doi: 10.1016/j.placenta.2008.01.013. Epub 2008 Mar 17. PMID:18343496; PMCID: PMC2475678
  - 15) Son DS, Wilson AJ, Parl AK, **Khabele D**. The effects of the histone deacetylase inhibitor romidepsin (FK2288) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. *Cancer Biol Ther* 2010;9:928-935. PMID:20404564; PMCID:PMC4047717
  - 16) Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, Yenamandra A, Locke K, Yuan JL, Bonine-Summers AR, Wells CE, Kaiser JF, Washington MK, Zhao Z, Wagner FF, Sun ZW, Xia F, Holson EB, **Khabele D**, Hiebert SW. Hdac3 is essential for the maintenance of chromatin structure and genome stability. *Cancer Cell* 2010;18:436-447. Doi: 10.1016/j.ccr.2010.10.022. PMID: 21075309; PMCID:PMC3004468
  - 17) Fadare, O, **Khabele, D**. Pleomorphic liposarcoma of the uterine corpus with focal smooth muscle differentiation. *Int J Gynecol Pathol* 2011;30: 282-287. PMID: 21464725
  - 18) Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, Bhaskara S, Hiebert SW, Schreiber SL, **Khabele D**. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. *Cancer Biol Ther* 2011;12:484-493. PMID:21738006; PMCID:PMC3218590
  - 19) Vargis E, Byrd T, Logan Q, **Khabele D**, Mahadevan-Jansen A. Sensitivity of Raman spectroscopy to normal patient variability. *J Biomed Opt* 2011;16:e117004. Doi: 10.1117/1.364210. PMID:22112136; PMCID:PMC3384271
  - 20) **Khabele D**, Fadare O, Liu AY, Wilson AJ, Wass E, Osteen K, Crispens MA. An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. *Int J Clin Exp Pathol* 2012;5:37-45. PMID: 22295145; PMCID:3267484
  - 21) Wilson AJ, Cheng YQ, **Khabele D**. Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy. *J Ovarian Res* 2012;5:e12.

- PMID:22531354; PMCID:PMC3394212
- 22) Vargis E, Tan YW, **Khabele D**, Mahadevan-Jansen A. Near-Infrared Raman Microspectroscopy Detects High-risk Human Papillomaviruses. *Transl Oncol* 2012;5(3):172-179. PMID:22741036; PMCID:PMC3384271
  - 23) Wilson AJ, Lalani AS, Wass E, Saskowski J, **Khabele D**. Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. *Gynecol Oncol* 2012;127(3):579-586. Doi: 10.1016/j.ygyno.2012.09.016. Epub 2012 Sep 23. PMID:23010348; PMCID:PMC3541411
  - 24) Fadare O, **Khabele D**. Salpingo-oophorectomy specimens for endometrial cancer staging: a comparative analysis of representative sampling versus whole tissue processing. *Hum Pathol* 2013;44:643-650. Doi: 10.1016/j.humpath.2012.07.015. Epub 2012 Oct 16. PMID:23084582; PMCID:PMC4079536
  - 25) Fadare O, Zheng W, Crispens MA, Jones HW, **Khabele D**, Gwin K, Liang SX, Mohammed K, Desouki MM, Parkash V, Hecht JL. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. *Am J Cancer Res* 2013;3:70-95. PMID:23359866; PMCID:PMC3555196
  - 26) Fadare O, Liang SX, Crispens MA, Jones HW 3rd, **Khabele D**, Gwin K, Zheng W, Mohammed K, Parkash V, Hecht JL, Desouki MM. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. *Hum Pathol* 2013;44:1508-1515. PMID:23465280; PMCID:PMC3888088
  - 27) Fadare O, Gwin K, Desouki MM, Crispens MA, Jones HW 3rd, **Khabele D**, Liang SX, Zheng W, Mohammed K, Hecht JL, Parkash V. The clinicopathologic significance of p53 and BAF- 250a (ARID1A) expression in clear cell carcinoma of the endometrium. *Mod Pathol* 2013;26:1101-1110. PMID:23524907; PMCID:PMC3886836
  - 28) Fadare O, James S, Desouki MM, **Khabele D**. Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas. *Ann Diagn Pathol* 2013;17:430-433. PMID:23706170; PMCID:PMC4079538
  - 29) Ayuso A, Fadare O, **Khabele D**. A case of extrauterine endometrial stromal sarcoma in the colon diagnosed three decades after hysterectomy for benign disease. *Case Rep Obstet Gynecol* 2013:e202458. Doi: 10.1155/2013/202458. Epub 2013 Apr 24. PMID:23710389; PMCID:PMC3655501
  - 30) Wilson AJ, Liu AY, Roland JT, Adebayo OB, Fletcher SA, Slaughter JC, Saskowski J, Crispens MA, Jones HW 3rd, James S, Fadare O, **Khabele D**. TR3 modulates platinum resistance in ovarian cancer. *Cancer Res* 2013;73:4758-4769. PMID:23720056; PMCID:PMC3944084
  - 31) Wells CE, Bhaskara S, Stengel KR, Zhao Y, Sirbu B, Chagot B, Cortez D, **Khabele D**, Chazin WJ, Cooper A, Jacques V, Rusche J, Eischen CM, McGirt LY, Hiebert SW. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. *PLoS One* 2013;8:e68915. PMID:23894374; PMCID:PMC3718806
  - 32) Zaidi SS, Lakhani VT, Fadare O, **Khabele D**. Adrenal Gland Metastasis Is an Unusual Manifestation of Endometrial Cancer. *Case Rep Surg*

- 2013:e4284562013. PMID:23984164; PMCID:PMC3748408
- 33) Basu A, Bodycombe NE, Jaime H, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, Stransky N, Kryukov GV, Dancik V, Barretina J, Garraway LA, Hon C SY, Muno B, Bittker JA, Stockwell BR, **Khabele D**, Stern AM, Clemons PA, Shamji AF, Schreiber SL. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. *Cell* 2013 Aug 29;154(5):1151-1161. Doi: 10.1016/j.cell.2013.08.003. PMID:23993102; PMCID:PMC3954635
- 34) Wilson AJ, Barham W, Saskowski J, Tikhomirov O, Chen L, Lee HJ, Yull F, **Khabele D**. Tracking NF-kappaB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. *J Ovarian Res* 2013;6:e63. PMID: 24020521; PMCID: PMC3846584
- 35) Cho M, Kabir SM, Dong Y, Lee E, Rice VM, **Khabele D**, Son DS. Aspirin Blocks EGF- stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells. *J Cancer* 2013;4:671-678. PMID:24155779; PMCID:PMC3805995
- 36) Hull PC, Williams EA, **Khabele D**, Dean C, Bond B, Sanderson M. HPV vaccine use among African American girls: Qualitative formative research using a participatory social marketing approach. *Gynecol Oncol* 2014;132 Suppl 1:S13-20. PMID:24491412; PMCID: PMC3966189
- 37) Collins Y, Holcomb K, Chapman-Davis E, **Khabele D**, Farley JH. Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. *Gynecol Oncol* 2014;133:353-361. PMID:24406291; PMCID: PMC4079541
- 38) **Khabele D**. The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer. *Frontiers in Oncology* 2014;4:e111. Doi: 10.3389/fonc.2014.00111.ecollection 2014. PMID:24904826; PMCID:PMC4033132
- 39) Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, **Khabele D**. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. *Gynecologic Oncol* 2014;133:599-606. PMID:24631446; PMCID:PMC4347923
- 40) Desouki MM, Kallas SJ, **Khabele D**, Crispens MA, Hameed O, Fadare O. Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas: diagnostic utility in distinguishing double primaries from metastatic tumors. *Int J Gynecol Pathol* 2014;33:274-281. PMID:24681739; PMCID:PMC4144715
- 41) **Khabele D**, Kabir SM, Dong Y, Lee E, Rice VM, Son DS. Preferential effect of akt2- dependent signaling on the cellular viability of ovarian cancer cells in response to EGF. *J Cancer* 2014;5:670-678. PMID:25258648; PMCID: PMC4174511
- 42) Desouki MM, **Khabele D**, Crispens MA, Fadare O. Ovarian mucinous tumor with malignant mural nodules: dedifferentiation or collision? *Int J Gynecol Pathol* 2015;34:19-24. PMID:25473748
- 43) Fadare O, Zhao C, **Khabele D**, Parkash V, Quick CM, Gwin K, Desouki MM. Comparative analysis of Napsin A, alpha-methylacyl-coenzyme a racemase

- (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumors. *Pathology* 2015;47:105-111. PMID:25551297
- 44) Carrillo AM, Hicks M, **Khabele D**, Eischen CM. Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells. *Mol Cancer Res* 2015;13:1197-2205. PMID: 25964101; PMID:PMC4543442
  - 45) Stewart ML, Tamayo P, Wilson AJ, Wang S, Chang YM, Kim JW, **Khabele D**, Shamji AF, Schreiber SL. KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. *Cancer Res* 2015;75:2897-2906. Doi: 10.1158/0008-5472.CAN-14-2860. Epub 2015 May 12. PMID:25968887; PMID:PMC4506246
  - 46) Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, **Khabele D**. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high- grade serous ovarian cancer. *Oncotarget* 2015; 6:21353-21368. PMID:25972361; PMID:4673270
  - 47) Wilson AJ, Saskowski J, Barham W, Yull F, **Khabele D**. Thymoquinone enhances cisplatin- response through direct tumor effects in a syngeneic mouse model of ovarian cancer. *J Ovarian Res* 2015;8:46. PMID:26215403; PMID:PMC4517540
  - 48) Hover LD, Young CD, Bhola NE, Wilson AJ, **Khabele D**, Hong CC, Moses HL, Owens P. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. *Cancer Lett* 2015;368:79-87. Doi: 10.1016.j.canlet.2015.07.032. Epub 2015 Jul 30. PMID:26235139
  - 49) Sanderson M, **Khabele D**, Brown CL, Harbi K, Alexander LR, Coker AL, Fernandez ME, Brandt HM, Fadden MK, Hull PC. Results of a Health Education Message Intervention on HPV Knowledge and Receipt of Follow-up Care among Latinas Infected with High-risk Human Papillomavirus. *J Health Care Poor Underserved* 2015; 26:1440-1455. PMID: 26548691
  - 50) Wilson AJ, Saskowski J, Barham W, **Khabele D**, Yull F. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer. *Mol Cancer* 2015; 14:e192. PMID: 26552746
  - 51) Nielsen TA, David SN, Desouki MM, Crispens MA, **Khabele D**. Incidental placenta increta at the time of prophylactic hysterectomy for Lynch syndrome: Insights into individualized decision-making and surgical timing. *Gynecologic Oncology Rep* 2015 14:20-22. PMID: 26793766
  - 52) Jiang X, Li H, Zhao P, Xie J, **Khabele D**, Xu J, Gore JC. Early detection of treatment-induced mitotic arrest using temporal diffusion magnetic resonance spectroscopy. *Neoplasia* 2016 18:387- 397. PMID: 27292027
  - 53) Wilson AJ, Sarfo-Kantanka K, Barrack T, Steck A, Saskowski J, Crispens MA, **Khabele D**. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib. *Gynecol Oncol* 143:143-151, 2016. PMID: 27444036
  - 54) Cozzi GD, Samuel JM, Fromal JT, Keene S, Crispens MA, **Khabele D**, Beeghly-Fadiel A. Thresholds and timing of pre-operative thrombocytosis and ovarian

- cancer survival: analysis of laboratory measures from electronic medical records. *BMC Cancer* 16:e612, 2016. PMID: 27502272
- 55) Sanderson M, Canedo JR, **Khabele D**, Fadden MK, Harris C, Beard K, Burress M, Pinkerton H, Jackson C, Mayo-Gamble T, Hargreaves MK, Hull PC. Pragmatic trial of an intervention to increase human papillomavirus vaccination in safety-net clinics. *BMC Public Health* 2017;17(1):158. PMID: 28153042
  - 56) Cozzi GD, Levinson RT, Toole H, Snyder MR, Deng A, Crispens MA, **Khabele D**, Beeghly- Fadiel A. Blood type, ABO genetic variants, and ovarian cancer survival. *PLoS One* 2017;12:e0175119. PMID: 28448592
  - 57) Choi H, Ignacio RMC, Lee ES, Wilson AJ, **Khabele D**, Son DS. Augmented Serum Amyloid A1/2 Mediated by TNF-induced NF- $\kappa$ B in Human Serous Ovarian Epithelial Tumors. *Immune Netw* 2017;17(2):121-127. PMID: 28458624
  - 58) Foxx AM, Zhu Y, Mitchel E, Nikpay S, **Khabele D**, Griffin MR. Cervical Cancer Screening and Follow-Up Procedures in Women Age <21 Years Following New Screening Guidelines. *J Adolesc Health* 2018;62(2):170-175. PMID: 29174874
  - 59) Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fathutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, **Khabele D**, Bitler B, Zhang R. BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancers. *Cell Reports* 2017;21(12):3398-3405. Doi: 10.1016/j.celrep.2017.11.095 PMID: 29262321
  - 60) Beeghly-Fadiel A, Wilson AJ, Keene S, El Ramahi M, Xu S, Marnett LJ, Fadare O, Crispens MA, **Khabele D**. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors. *J Ovarian Res* 2018 Feb 27;11(1):17. Doi: 10.1186/s13048-018-0389-9. PMID: 29482584
  - 61) Wilson AJ, Stubbs, M, Liu P, Ruggeri B, **Khabele D**. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. *Gynecol Oncol* 2018;149(3):575-584. Doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20. PMID: 29567272
  - 62) Jewell A, McMahan M, **Khabele D**. Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer. *Cancers (Basel)*.2018 Sep 1; 10(9):296. Doi: 10.3390/cancers10090296. PMID: 30200420
  - 63) Gupta V, Yull F, **Khabele D**. Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy. *Cancers* 2018;29;10(10):366. Doi: 10.3390/cancers10100366. PMID: 30274280
  - 64) Elsamadicy EA, Schneider MK, Hull PC, **Khabele D**. Human papillomavirus vaccination completion rates among gynecological providers: an institutional retrospective review. *Hum Vaccin Immunother* 2019;15(7-8):1851-1855. Doi: 10.1080/21645515.2019.1619405. Epub 2019 Jun 11. PMID: 31091165
  - 65) Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, **Khabele D**, Marnett LJ. Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer. *ACS Omega* 2019;4(5):9251-9261. PMID: 31172046
  - 66) Petersen S, Wilson AJ, Hirst J, Roby KF, Fadare O, Crispens MA, Beeghly-Fadiel A, **Khabele D**. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes. *Gynecol Oncol* 2020

- May;157(2):405-410. Doi: 10.1016/j.ygyno.2020.01.038. Epub 2020 Feb 7.  
PMID: 32044108
- 67) Berry C, **Khabele D**, Johnson-Mann C, Henry-Tillman R, Joseph KA, Turner P, Pugh C, Fayanju OM, Backhus L, Sweeting R, Newman EA, Oseni T, Hasson RM, White C, Cobb A, Johnston FM, Stallion A, Karpeh M, Nwariaku F, Rodriguez LM, Jordan AH. A Call to Action: Black/African American Women Surgeon Scientists, Where are They? *Ann Surg* 2020 Jul;272(1):24-29. PMID: 32209893. Doi: 10.1097/SLA.0000000000003786. PMID 32209893
- 68) Ma Y, Chen P, Drisko JA, **Khabele D**, Godwin AK, Chen Q. Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer. *Oncol Lett* 2020; Apr;19(4):2629-2638. Doi: 10.3892/ol.2020.11364. Epub 2020 Jan 31. PMID: 32218813
- 69) Asem M, Young A, Oyama C, ClaireDeLaZerda A, Liu Y, Ravosa MJ, Gupta V, Jewell A, **Khabele D**, Stack MS. Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer. *Sci Rep* 2020 Jul 17;10(1):11913. PMID: 32681052. Doi: 10.1038/s41598-020-68639-2.
- 70) Crown A, Berry C, **Khabele D**, Fayanju OM, Cobb A, Backhus L, Smith R, Sweeting R, Hasson R, Johnson-Mann C, Oseni T, Newman EA, Turner P, Karpeh M, Pugh C, Jordan AH, Henry-Tillman R, Joseph KA. The Role of Race and Gender in the Career Experiences of Black/African American Academic Surgeons: A Survey of the Society of Black Academic Surgeons and a Call to Action. *Ann Surg* 2020 Sep 15. doi: 10.1097/SLA.0000000000004502. Online ahead of print. PMID: 32941287
- 71) Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, **Khabele D**, Mosammaparast N, Vindigni A. Homologous recombination deficiency real-time clinical assays, ready or not? *Gynecol Oncol* 2020 Dec;159(3):877-886. doi: 10.1016/j.ygyno.2020.08.035. Epub 2020 Sep 20. PMID: 32967790
- 72) Hufnagel DH, Wilson AJ, Saxon J, Blackwell TS, Watkins J, **Khabele D**, Crispens MA, Yull FE, Beeghly-Fadiel A. Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis. *Biomark Res* 2020 Sep 15;8:45. Doi: 10.1186/s40364-020-00227-y. eCollection 2020. PMID: 32974032
- 73) Hoover AA, Hufnagel DH, Harris W, Bullock K, Glass EB, Liu E, Barham W, Crispens MA, **Khabele D**, Giorgio TD, Wilson AJ, Yull FE. Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer. *BMC Cancer* 2020; Oct 7;20(1):970. Doi: 10.1186/s12885-020-07450-8. PMID: 33028251.
- 74) **Khabele D**, Holcomb K, Connors NK, Bradley L. A Perspective on James Marion Sims, MD, and Antiracism in Obstetrics and Gynecology. *J Minim Invasive Gynecol*. 2021 Feb;28(2):153-155. Doi:10.1016/j.jmig.2020.10.027. Epub 2020 Nov 6. PMID: 33166660.
- 75) Petersen S, Shahiri P, Jewell A, Spoozak L, Chapman J, Fitzgerald-Wolff S, Lai SM, **Khabele D**. Disparities in ovarian cancer survival at the only NCI-designated

- cancer center in Kansas. *Am J Surg*. 2020:S0002-9610(20)30787-X. PMID: 33309256.
- 76) Kuroki LM, Morris DH, Greenwade M, Landon M, Hagemann AR, Thaker PH, Massad LS, McCourt CK, Fuh KC, Powell MA, Mutch DG, **Khabele D**, Vanderlan JR. Impact of employment and insurance status on distress in gynecologic oncology patients. *Gynecol Oncol*. 2021 May;161(2):477-482. Doi: 10.1016/j.ygyno.2021.01.038. Epub 2021 Feb 3. PMID: 33546868
  - 77) Johns EA, Stanley JA, Toboni MD, Schwarz JK, Zhang F, Hagemann AR, Fuh KC, Thaker H, McCourt CK, Mutch DG, Powell MA, **Khabele D**, Kuroki LM. Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer. *Gynecol Oncol Rep*. 2021 Jun 9;37:100808. Doi: 10.1016/j.gore.2021.100808. eCollection 2021 Aug. PMID: 34169134
  - 78) Gupta VG, Hirst J, Petersen S, Roby KF, Kusch M, Zhou H, Clive ML, Jewell A, Pathak HB, Godwin AK, Wilson AJ, Crispens MA, Cybulla E, Vindigni A, Fuh KC, **Khabele D**. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. *Gynecol Oncol*. 2021 Jul;162(1):163-172. Doi: 10.1016/j.ygyno.2021.04.015. Epub 2021 Apr 16. PMID:33867143
  - 79) Chapman-Davis E, **Khabele D**. A Race-Conscious Analysis of the Use of Transvaginal Ultrasonography in the Evaluation of Postmenopausal Bleeding. *JAMA Oncol*. 2021 Aug 1;7(8):1165-1166. doi: 10.1001/jamaoncol.2021.1681. PMID: 34264293.
  - 80) Hufnagel DH, **Khabele D**, Yull FE, Hull PC, Schildkraut J, Crispens MA, Beeghly-Fadiel A. Increasing Area Deprivation Index negatively impacts ovarian cancer survival. *Cancer Epidemiol*. 2021 Oct;74:102013. doi: 10.1016/j.canep.2021.102013. Epub 2021 Aug 23. PMID: 34438316.
  - 81) Brubaker L, Marsh E, Cedars MI, Fenner D, Murtha A, Goff B, **Khabele D**. Promotion of gender equity in obstetrics and gynecology: principles and practices for academic leaders. *Am J Obstet Gynecol*. 2022 Feb;226(2):163-168. doi: 10.1016/j.ajog.2021.09.035. Epub 2021 Oct 2. PMID: 34610320.
  - 82) Toboni MD, Lomonosova E, Bruce SF, Tankou JI, Mullen MM, Schab A, Opl A, Noia H, Wilke D, Kuroki LM, Hagemann AR, McCourt CK, Thaker PH, Powell MA, **Khabele D**, Mutch DG, Fuh KC. Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer. *Cancers (Basel)*. 2021 Nov 23;13(23):5877. doi: 10.3390/cancers13235877. PMID: 34884986; PMCID: PMC8656641.
  - 83) Wilson AJ, Gupta VG, Liu Q, Yull F, Crispens MA, **Khabele D**. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer. *Neoplasia*. 2022 Feb;24(2):63-75. doi: 10.1016/j.neo.2021.12.002. Epub 2021 Dec 20. PMID: 34933276; PMCID: PMC8702851.
  - 84) Bruce SF, Huysman B, Bharucha J, Massad LS, Mullen M, Hagemann AR, Fuh KC, McCourt CK, Thaker PH, **Khabele D**, Powell MA, Mutch DG, Kuroki LM. Impact of the COVID-19 pandemic on referral to and delivery of gynecologic oncology care. *Gynecol Oncol Rep*. 2022 Feb;39:100928. doi:

- 10.1016/j.gore.2022.100928. Epub 2022 Jan 7. PMID: 35024405; PMCID: PMC8739812.
- 85) Keshinro A, Butler P, Fayanju O, **Khabele D**, Newman E, Greene W, Ude Welcome A, Joseph KA, Stallion A, Backhus L, Frangos S, DiMaggio C, Berman R, Hasson R, Rodriguez LM, Stain S, Bukur M, Klein MJ, Henry-Tillman R, Barry L, Oseni T, Martin C, Johnson-Mann C, Smith R, Karpeh M, White C, Turner P, Pugh C, Hayes-Jordan A, Berry C. Examination of Intersectionality and the Pipeline for Black Academic Surgeons. *JAMA Surg.* 2022 Apr 1; 157(4):327-334. Doi: 10.1001/jamasurg.2021.7430. PMID: 35138327
- 86) Glass EB, Hoover AA, Bullock KK, Madden MZ, Reinfeld BI, Harris W, Parker D, Hufnagel DH, Crispens MA, **Khabele D**, Rathmell WK, Rathmell JC, Wilson AJ, Giorgio TD, Yull FE. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. *BMC Cancer.* 2022 May 6; 22(1):497. Doi: 10.1186/s12885-022-09612-2. PMID: 35513776
- 87) Wilhite AM, Baca Y, Xiu J, Paladugu R, ElNaggar A, Brown J, Winer IS, Morris R, Erickson B, Olawaiye A, Powell M, Korn W, Rocconi R, **Khabele D**, Jones NL. Molecular profiles of endometrial cancer tumors among Black patients. *Gynecol Oncol.* 2022 Jul; 166(1):108-116. Doi: 10.1016/j.ygyno.2022.04.014. Epub 2022 Apr 28. PMID: 35490034
- 88) Bruce SF, Cho K, Noia H, Lomonosova E, Stock EC, Oplt A, Blachut B, Mullen MM, Kuroki LM, Hagemann AR, McCourt CK, Thaker PH, **Khabele D**, Powell MA, Mutch DG, Shriver LP, Patti GJ, Fuh KC. GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis. *Mol Cancer Ther.* 2022 Aug 2; 21(8):1348-1359. Doi: 10.1158/1535-7163.MCT-21-0704. PMID: 35588308
- 89) Zamorano AS, Mazul AL, Marx C, Mullen MM, Greenwade M, Massad SL, McCourt CK, Hagemann AR, Thaker PH, Fuh KC, Powell MA, Mutch DG, **Khabele D**, Kuroki LM. Community access to primary care is an important geographic disparity among ovarian cancer patients undergoing cytoreductive surgery. *Gynecol Oncol Rep.* 2022 Oct 3; 44:101075. Doi: 10.1016/j.gore.2022.101075. eCollection 2022 Dec. PMID: 36217326
- 90) Schreiber CA, **Khabele D**, Gehrig PA. The Dobbs v Jackson Women's health Organization Supreme Court Decision-Concerns, Challenges, and Consequences for Health Care. *JAMA Surg.* 2023 Mar 1;158(3):229-230. doi: 10.1001/jamasurg.2022.5714. PMID: 36318215
- 91) Buckley E, Mullen MM, Nizamuddin RA, Stein JH, Kuroki LM, Fuh KC, Hagemann AR, McCourt CK, Mutch DG, **Khabele D**, Powell MA, Ippolito JE, Thaker PH. High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer. *Gynecol Oncol.* 2022 Dec; 167(3):496-501. Doi: 10.1016/j.ygyno.2022.09.011. Epub 2022 Sep 28. PMID: 36180305
- 92) Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook

- LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCs Group; Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, **Khabele D**, Kommos FKF, Kruitwagen RFP, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Schoemaker MJ, Shah M, Sharma R, Shvetsov YB, Singh N, Sonke GS, Steele L, Stewart CJR, Sundfeldt K, Swerdlow AJ, Talhouk A, Tan A, Taylor SE, Terry KL, Tołoczko A, Traficante N, Van de Vijver KK, van der Aa MA, Van Gorp T, Van Nieuwenhuysen E, van Wagenveld L, Vergote I, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Wu AH, Benitez J, Berchuck A, Candido Dos Reis FJ, DeFazio A, Fasching PA, Goode EL, Goodman MT, Gronwald J, Karlan BY, Kommos S, Menon U, Sinn HP, Staebler A, Brenton JD, Bowtell DD, Pharoah PDP, Ramus SJ, Köbel M. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. *Cancer*. 2023 Mar 1;129(5):697-713. doi: 10.1002/cncr.34582. Epub 2022 Dec 26. PMID: 36572991  
Free PMC article
- 93) Compadre AJ, van Biljon LN, Valentine MC, Llop-Guevara A, Graham E, Fashemi B, Herencia-Roperio A, Kotnik EN, Cooper I, Harrington SP, Kuroki LM, McCourt CK, Hagemann AR, Thaker PH, Mutch DG, Powell MA, Sun L, Mosammamarast N, Serra V, Zhao P, Lomonosova E, **Khabele D**, Mullen MM. RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer. *Clin Cancer Res*. 2023 Apr 25:CCR-22-3335. doi: 10.1158/1078-0432.CCR-22-3335. Online ahead of print. PMID: 37097615
- 94) van Biljon L, Fashemi B, Rodriguez J, Graham O, Compadre A, Fuh K, **Khabele D**, Mullen M. Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays. *Vis Exp*. 2023 Feb 24;(192). doi: 10.3791/64881. PMID: 36912550
- 95) Graham O, Rodriguez J, van Biljon L, Fashemi B, Graham E, Fuh K, **Khabele D**, Mullen M. J. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids. *Vis Exp*. 2023 Jan 6;(191). doi: 10.3791/64878. PMID: 36688549
- 96) Suraju MO, McElroy L, Moten A, Obeng-Gyasi S, Alimi Y, Carter D, Foretia DA, Stapleton S, Yilma M, Reid VJ, Tetteh HA, **Khabele D**, Rodriguez LM, Campbell A, Newman EA. A framework to improve retention of Black surgical trainees: A Society of Black Academic Surgeons white paper. *Am J Surg*. 2023 Jul 16:S0002-9610(23)00336-7. doi: 10.1016/j.amjsurg.2023.07.022. Online ahead of print. PMID: 37495467
- 97) Kotnik EN, Mullen MM, Spies NC, Li T, Inkman M, Zhang J, Martins-Rodrigues F, Hagemann IS, McCourt CK, Thaker PH, Hagemann AR, Powell MA, Mutch

- DG, **Khabele D**, Longmore GD, Mardis ER, Maher CA, Miller CA, Fuh KC. Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival. *Commun Biol.* 2023 Jul 3;6(1):688. doi: 10.1038/s42003-023-05026-3. PMID: 37400526
- 98) Klingensmith ME, Gosman GG, **Khabele D**, Brinkmann BS. Roe v Wade, Dobbs, and the Future of Graduate Medical Education. *J Grad Med Educ.* 2023 Jun;15(3):407-410. doi: 10.4300/JGME-D-23-00279.1. Epub 2023 Jun 14. PMID: 37363655
- 99) Fashemi BE, van Biljon L, Rodriguez J, Graham O, Mullen M, **Khabele D**. Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing. *J Vis Exp.* 2023 Sep 15;(199). doi: 10.3791/65068.PMID: 37782106
- 100) Schab AM, Greenwade MM, Stock E, Lomonosova E, Cho K, Grither WR, Noia H, Wilke D, Mullen MM, Hagemann AR, Hagemann IS, Thaker PH, Kuroki LM, McCourt CK, **Khabele D**, Powell MA, Mutch DG, Zhao P, Shriver LP, Patti GJ, Longmore GD, Fuh KC, Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins. *Mol Cancer Res.* 2023 Nov 1;21(11):1234-1248. doi: 10.1158/1541-7786.MCR-23-0347.PMID: 37527178
- 101) Hicks ML, Hicks MM, Mathews RP, **Khabele D**, Clare C, Balogun OA, Lawson YR, Tillman RH, Butler R, Spann CO, Parham GP. Racial disparities in endometrial cancer: Where are we after 26 years?, *Gynecol Oncol.* 2024 Feb 20;184:236-242. doi: 10.1016/j.ygyno.2024.01.054. Online ahead of print. PMID: 38382150
- 102) Hicks ML, Matthews RP, Clare CA, Lawson YR, **Khabele D**, Hicks MM, Spann CO, Parham GP., The impact of Black founding fathers on the specialty of gynecologic oncology. *Gynecol Oncol.* 2024 Feb 16;185:42-45. doi: 10.1016/j.ygyno.2024.02.006. Online ahead of print. PMID: 38367302
- 103) Standing D, Dandawate P, Gunewardena S, Covarrubias-Zambrano O, Roby KF, **Khabele D**, Jewell A, Tawfik O, Bossman SH, Goodwin AK, Weir SJ, Jensen RA, Anant S., Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer. *Cell Death Dis.* 2024 May;15(5):362. Doi:10.1038/s41419-024-06717-3. PMID: 38796478.
- 104) Graham O, Rodriguez J, Abbott R, Lomonosova E, Fashemi B, Drexler R, Grither W, Rodriguez K, Compadre A, Loeb M, Sanders B, Kuroki L, Hagemann AR, McCourt C, Thaker PH, Fuh K, Powell MA, Hagemann IS, Mutch DG, **Khabele D**, Mullen MM. A toolkit for a modern gynecologic oncology tissue bank. *Gynecol Oncol.* 2024 Oct;189:1-8. Doi:10.1016/j.ygyno.2024.07.001. Epub 2024 Jul 5. PMID:38971004
- 105) Wilhite AM, Wu S, Xiu J, Gibney GT, Phung T, In GK, Herzog TJ, **Khabele D**, Erickson BK, Brown J, Rocconi RP, Pierce JY, Scalici JM, Jones NL. A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma. *Gynecol Oncol.* 2024 Sep;188:13-21. doi: 10.1016/j.ygyno.2024.06.002. Epub 2024 Jun 10. PMID: 38861917
- 106) Mullen MM, Grither WR, Millimet H, Mutch DG, Hagemann AR, McCourt CK, Powell MA, Thaker PH, **Khabele D**, Kuroki LM. Prophylactic antibiotics for

- excision of premalignant vulvar lesions: A pilot randomized controlled trial. *Gynecol Oncol Rep.* 2024 Aug 8;55:101476. doi: 10.1016/j.gore.2024.101476. eCollection 2024 Oct. PMID: 39229484
- 107) Gupta VG, Roby KF, Pathak HB, Godwin AK, Gunewardena S, **Khabele D**. The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model. *BMC Cancer.* 2025 Feb 11;25(1):233. Doi:10.1186/s12885-025-13640-z. PMID: 39930466
- 108) Ross WY, Buday S, Yakel E, **Khabele D**, Balls-Berry J, As-Saine S, Colditz G, Baumann AA. Does interdisciplinary group care for the treatment of endometriosis improve pain interference: protocol for pilot randomized controlled trial at an urban academic medical centre. *BMJ Open.* 2025 Mar 5;15(3):e097372. Doi: 10.1136/bmjopen-2024-097372. PMID: 40044193
- 109) Schab A, Compadre A, Drexler R, Loeb M, Rodriguez K, Brill J, Harrington S, Sandoval C, Sanders B, Kuroki L, McCourt C, Hagemann AR, Thaker P, Mutch D, Powell M, Serra V, Hagemann IS, Walts AE, Karlan BY, Orsulic S, Fuh K, Sun L, Verma P, Lomonosova E, Zhao P, **Khabele D**, Mullen M. Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer. *bioRxiv [Preprint].* 2024 Nov 25:2024.11.21.624682. doi: 10.1101/2024.11.21.624682. PMID: 39651311  
*J Clin Invest.* 2025 May 20;135(13):e189511. Doi 10.1172/JC189511. Ecollection 2025 Jul 1. PMID: 40392598
- 110) Miceska S, Grašič Kuhar C, Frković Grazio S, Škof E, Krishnamoorthy P, **Khabele D**, Kloboves Prevodnik V. Association of Tumor-Infiltrating Lymphocytes and Inflammation Status with Survival Outcome in Patients with High-Grade Serous Ovarian Carcinoma. *Cancers (Basel).* 2025 Jul 8;17(14):2269. doi: 10.3390/cancers17142269. PMID: 40723153
- 111) Lomonosova E, Loeb M, Rodriguez K, van Biljon LN, Brill J, Schab A, Minett M, Barron J, Bittner M, Park J, Drexler R, Sandoval C, Opl A, Gallup E, Thuthika PK, Sadeghipour N, Wu S, Oberley MJ, Sanders B, Kuroki L, McCourt C, Hagemann AR, Thaker P, Mutch D, Powell M, Hagemann IS, Ilagan MXG, Fuh K, Verma P, Schärer OD, Mosammaparast N, **Khabele D**, Mullen MM. Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms. *bioRxiv [Preprint].* 2025 Aug 6:2025.08.04.668450. doi: 10.1101/2025.08.04.668450. PMID: 40799594
- 112) Ota Y, Gupta V, Fashemi BE, Akande M, Babu P, Thuthika P, Elizagaray ML, Sun L, Sanders B, Kuroki LM, McCourt CK, Hagemann AR, Hagemann IS, Thaker PH, Mutch DG, Powell MA, Hyrc K, Verma P, Krais J, Bitler BG, Mullen M, **Khabele D**. Targeting RAD52 overcomes PARP inhibitor resistance in preclinical Brca2-deficient ovarian cancer model. *bioRxiv [Preprint].* 2025 Sep 26:2025.09.24.678351. doi: 10.1101/2025.09.24.678351. PMID: 41040355
- 113) Aubuchon LN, Wong DH, Ramakrishnan NM, Reddy R, Compadre A, Lomonosova E, Jackson KE, Kemper D, Mehta V, Zoberi K, **Khabele D**, Christie EL, Mullen MM, Verma P. Targeting ALC1 can safely expand the therapeutic utility of PARP inhibitors across high-grade serous ovarian cancers. *bioRxiv*

- [Preprint]. 2025 Dec 8:2025.12.04.692458. doi: 10.64898/2025.12.04.692458.PMID: 41415416
- 114) Harrington SP, Romani J, Jatoi A, Weroha SJ, Mariani A, Cliby WA, Bakkum-Gamez JN, **Khabele D**, Gaspar-Maia A. MECOM amplified endometrial cancer, a novel subset of copy number high tumors associated with poor prognosis. *Gynecol Oncol Rep*. 2025 Nov 16;62:101993. doi: 10.1016/j.gore.2025.101993. eCollection 2025 Dec. PMID: 41340866
- 115) Schiff JP, Raju-Salicki S, McKinnish TR, Adekunle O, Stavroulaki K, Hatscher C, Sun L, Huang Y, Huecker J, Lew D, Thaker PH, McCourt CK, Massad LS, Kuroki LM, Hagemann AR, Powell MA, **Khabele D**, Mutch D, Badiyan SS, Lin A, Schwarz JK, Markovina S, Contreras JA. Phase I Clinical Trial of De-escalated Conformal Radiation Expedited Sequentially with Chemotherapy for Advanced Endometrial Cancer (DeCRESCEndo). *Int J Radiat Oncol Biol Phys*. 2026 Jan 21:S0360-3016(26)00087-8. doi: 10.1016/j.ijrobp.2026.01.015. Online ahead of print. PMID: 41577208

### **Reviews, Chapters, and Editorials, including Invited Publications (selected)**

- 1) Huang G, Einstein M, **Khabele D**, Goldberg, GL. Serum Biomarkers for Epithelial Ovarian Cancer. *Women's Oncology Review* 2003;3: 117-22
- 2) Sukumvanich P, **Khabele D**, Goldberg GL. Current issues regarding tamoxifen and the genital tract: a review. *Women's Oncology Review* 2004;4: 85-94 2
- 3) **Khabele D**. Human Papillomavirus (HPV) and Cervical Cancer: What you need to know. *Women's VU* 2007;29: 7
- 4) Gonzalez R, Chamberlain BK, Giannico G, Fadare O, Crispens MA, **Khabele D**, Desouki MM. Ovarian Serous Borderline Tumor Identified in Endometrial Biopsy: A Case Report. *Gynecology and Obstetrics* 2013;3:e5
- 5) **Khabele D** and New M (2013). *Chapter 12: Gynecologic Oncology*. In: Tarascon Obstetrics and Gynecology (T. Callahan). Jones & Bartlett Learning, Burlington, MA.
- 6) **Khabele D** (2013). *Ovarian and Fallopian Tube Tumors*. In: Blueprints Obstetrics and Gynecology 6<sup>th</sup> ed (T. Callahan and A. Caughey, eds). Lippincott Williams & Wilkins, Baltimore, MD, pp 392-404.
- 7) **Khabele, D** and Beech D (2009). *Clinical Trials and Translational Applications in Cancer Therapy*. In *Pharmaceutical Perspectives of Cancer Therapeutics*. pp 673-683.
- 8) Wood S, Bardawil E, **Khabele, D** (2025). *Gynecologic Surgery*. In: Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 22<sup>nd</sup> Edition. *Chapter 120, pp 2038-2064*. Elsevier.

### **Books**

- 1) Chi DS, **Khabele, D**, Dizon D, Yashar C (2025). *Principles and Practice of Gynecologic Oncology*. 8th Edition. Wolters Kluwer.

### **Audiovisual/Media (selected)**

- 1) Fadare O. and **Khabele D.** (2012 - 2020). Ovarian Cancer. Molecular Profiling of Epithelial Ovarian Cancer. My Cancer Genome. Genetically Informed Cancer Medicine. [www.mycancergenome.org](http://www.mycancergenome.org)
- 2) Podcast Interview. OBGYN Rocks. Let's Get to Work. <https://creators.spotify.com/pod/show/washuobgynrocks/episodes/Dr--Dineo-Khabele--Lets-Get-to-Work-ehqout/a-a2uamuk> August 2020.
- 3) Podcast Interview. No Capes Needed. Womxn's Health Collaborative <https://pod.link/1531811313/episode/0e644d49de73f565e4e622b3feb2ad23> November 2020.
- 4) Community Tweet Chat. Disparities in Gyn Cancer Diagnosis and Treatment, #gynscsm, Gynecologic Cancer social media. March 2021.
- 5) Webisode # 2, EmpowHER Series, Disparities When It Comes to Gynecologic Cancers & How We can Close the Gap <https://youtu.be/oezimmqqCN8?feature=shared> March 2021.
- 6) **Khabele D.** Racial and Ethnic Health Disparities, Women, and Cancer. [www.medscape.com](http://www.medscape.com) Online article for CME: August 23, 2005 through August 23, 2006.
- 7) Fox2News Live, Black women and Uterine Cancer <https://www.ksdk.com/video/entertainment/television/show-me-st-louis/new-study-shows-black-women-dying-of-cancer-at-higher-rates/63-3963ebad-6c56-4fe5-9f83-b9e51efcb7b2> June 2022.
- 8) Webinar, Society for Women's Health Research (SWHR), Ovarian Cancer Screening: More than a Pelvic Exam. Value of Diagnostics within Women's Health. December 2022.
- 9) KMOV4 Special Feature, Tackle disparities impacting people of color. <https://www.firstalert4.com/2023/02/28/washu-med-schools-first-black-department-head-looks-tackle-disparities-impacting-people-color/> April 2023.
- 10) Podcast Interview. Gynecologic Oncology July Journals. Elsevier. August 2023.
- 11) Podcast Interview. The Marathon of Medicine: What sports teach us about resiliency, recovery, and how to avoid being benched. <https://creators.spotify.com/pod/show/washuobgynrocks/episodes/The-Marathon-of-Medicine-What-sports-teach-us-about-resiliency--recovery--and-how-to-avoid-being-benched-e2gab12/a-a80i5kc> February 2024.
- 12) Podcast Interview. Nine PBS. Listen St. Louis with Carol Daniel. Prevalence of Fibroids among Black Women. April 2024.
- 13) KSDK Interview, Show Me STL, ACS Study (American Cancer Society-Black women and cancer- ABC News) June 2024

## Abstracts

- 1) **Khabele D,** Abu-Rustum N, Almadrones L, Barakat R, Curtin J. A surveillance strategy for detecting recurrent ovarian cancer after negative second-look surgery. Poster Presentation, 29th Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, February 1998
- 2) **Khabele D,** Zelmanovich J, Anderson P, Fields A, Runowicz C, Goldberg G. Evaluation of intraperitoneal interferon in patients with symptomatic ascites and non-ovarian gynecologic malignancies. Poster Presentation, 90th Annual Meeting

- of the American Association for Cancer Research, Philadelphia, PA, April 1999
- 3) **Khabele D**, Heyer J, Kneitz S, Lia M, Goldberg G, Runowicz C, Kucherlapati R. A cDNA microarray system: potential applications in ovarian cancer. Poster Presentation, 31st Annual Meeting of the Society for Gynecologic Oncologists, San Diego, CA, February 2000
  - 4) **Khabele D**, Heyer J, Kneitz S, Lia M, Goldberg G, Runowicz C, Kucherlapati R. A cDNA microarray system: potential applications in ovarian cancer. Poster Presentation, SmithKline Beecham, Gynecologic Oncology Fellow's Forum, San Diego, CA, February 2000
  - 5) **Khabele D**, Heyer J, Merscher S, Solaimanzadeh S, Zhang W, McDaid H, Horwitz S, Anderson, P, Fields A, Goldberg G, Runowicz C, Kucherlapati R. Analysis, by cDNA Microarrays, of Ovarian Cancer Cells After Treatment With Etoposide. Poster Plenary Presentation, GlaxoSmithKline Gynecologic Oncology Fellow's Forum, Tuscon, AZ, February 2001
  - 6) **Khabele D**, Heyer J, Merscher S, Solaimanzadeh S, Zhang W, McDaid H, Horwitz S, Anderson, P, Fields A, Goldberg G, Runowicz C, Kucherlapati R. Analysis, by cDNA Microarrays, of Ovarian Cancer Cells After Treatment With Etoposide. Poster Presentation, 32nd Annual Meeting of the Society for Gynecologic Oncologists, Nashville, TN, March 2001
  - 7) **Khabele D**, Lopez-Jones M, Zhang W, Solaimanzadeh S, Horwitz S, Runowicz CD, Kucherlapati R, Augenlicht L. Patterns of gene expression in ovarian cancer cells treated with Etoposide. Poster Presentation, 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 2002
  - 8) **Khabele D**, Gorelick C, Lopez-Jones M, Alvino A, Augenlicht L, Goldberg G, Romney S. Lipid signaling gene targets of Coenzyme Q10 (CoQ10) in HeLa cells. Poster Presentation, 34th Annual Meeting of the Society for Gynecologic Oncologists, New Orleans, LA, January 2003
  - 9) **Khabele D**, Lopez-Jones M, Gorelick C, Wilson A, Yang W, Livne K, Goldberg G, Augenlicht L, Romney S. Lipid signaling in HeLa cells after treatment with Coenzyme Q10 (CoQ10). Poster Presentation, 94th Annual Meeting of the American Association for Cancer Research, Toronto ONT, Canada, April 2003
  - 10) **Khabele D**, Goldman N, Danish A, Anderson P, Goldberg G, Fields A. RT sandwiched between chemotherapy in uterine papillary serous carcinoma. Poster Presentation, 39th Annual Meeting of the American Society of Clinical Oncology, Chicago IL, May 2003
  - 11) **Khabele D**, Chan F, Fields A, Yang W, Livne K, Lopez-Jones M, Goldberg G, Mariadason J, Leonard Augenlicht. Expression of Histone Deacetylase 1 (HDAC 1) in Ovarian Tissue. Plenary presentation, 4<sup>th</sup> Annual Meeting of the International Conference on Ovarian Cancer, New York, NY, September 2003
  - 12) Gross S, Dar P, Livne K, Ferreira J, Gross B, **Khabele D**. Gene expression profiles of the TNF-related apoptotic pathway in down syndrome placentae. Poster Presentation, 53rd Annual Meeting of the American Society of Human Genetics, Los Angeles, CA, November 2003
  - 13) Dar P, Ferreira J, Livne K, Segal J, **Khabele D**, Gross B, Gross S. Use of microarray technology to identify differential gene expression in down syndrome placentae: validation of methodology. Poster Presentation, 53rd Annual Meeting

- of the American Society of Human Genetics, Los Angeles, CA, November 2003
- 14) **Khabele D**, Akoma U, Constant P, Yang W, Lopez-Jones M, Livne K, Augenlicht L, Goldberg G. Keratin 8, and tumor necrosis factor apoptotic genes in ovarian tissue. Poster Presentation, 35th Annual Meeting of the Society for Gynecologic Oncologists, San Diego, CA, February 2004
  - 15) **Khabele D**, Chan F, Fields A, Yang W, Livne K, Lopez-Jones M, Goldberg G, Mariadason J, Leonard Augenlicht. Expression of Histone Deacetylase 1 (HDAC 1) in ovarian tissue. Poster Presentation, 35th Annual Meeting of the Society for Gynecologic Oncologists, San Diego, CA, February 2004
  - 16) Klugman S, **Khabele D**, Liang J, Livne K, Lopez-Jones M, Gross B, Reznik S, Gross S. Expression of Keratin 8 and TRAIL in Down Syndrome placentas. Oral Presentation, 54<sup>th</sup> Annual Meeting of the American Society of Human Genetics, San Diego, CA, October 2004
  - 17) Ochieng J, Baptiste T, **Khabele D**. Fetuin-A/annexin interaction is a critical growth signaling pathway in ovarian carcinoma cells. Poster Presentation, 96th Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 2005
  - 18) Green-Jarvis B, O'Brien C, Parl A, Montgomery Rice V., and **Khabele D**. HDAC inhibitors and VEGF in Epithelial Ovarian Cancer. Anti-Angiogenesis and Drug Delivery to Tumors. Waltham, MA, November 2005
  - 19) Miller-Torbert T, Marrs C, O'Brien C, Roby K, **Khabele D**, and Montgomery Rice V. Histone deacetylase inhibitor, FK228 inhibits VEGF and HDAC Activity a Mouse Ovarian Cancer Cell Line. Poster Presentation, 53rd Annual Scientific Meeting, Society for Gynecological Investigation, Toronto, CA, March 2006
  - 20) O'Brien, C, Green-Jarvis B, and **Khabele, D**. The Effects of Aspirin (ASA) and Paclitaxel (PTX) in COX-1 expressing ovarian cancer cells. Oral Presentation, Vanderbilt-Ingram Cancer Center Retreat: Inflammation and Cancer, May 2006
  - 21) **Khabele D**, Son DS, O'Brien C, Marrs C, Miller-Torbert T, Parl A, Montgomery Rice, V. The molecular and cellular effects of ASA and taxol in COX-1 expressing ovarian cancer cells. Oral Presentation, 10<sup>th</sup> International RCMC Symposium, San Juan, Puerto Rico, December 2006
  - 22) **Khabele D**. Building a Women's Cancer Program in the Department of Obstetrics and Gynecology at Meharry Medical College. Poster Presentation, Cancer Health Disparities Summit, Washington, DC, July 2007
  - 23) **Khabele D** and Gunter N. Community Partnership Campaign to Eliminate Cervical Cancer in Women of Color. Oral Presentation, 2007 Minority Women's Health Summit, Washington, DC, August 2007
  - 24) **Khabele D**. Community-Based Research Approach to Eliminate Health Care Disparities in Cervical Cancer. Oral Presentation, 105<sup>th</sup> Annual Convention and Scientific Assembly, Honolulu, HI, August 2007
  - 25) **Khabele D**, Egger M, Wujcik D, Overlock M, Campbell T, Dewey M. Promoting Cervical Cancer Screening Services through a Breast Cancer Screening Program. Poster Presentation, 2007 AACR Conference on Cancer Health Disparities, Atlanta, GA, November 29, 2007
  - 26) **Khabele D**, Son D, Daikoku T, Parl A, Dey SK. Targeting cyclooxygenase-1 (COX-1) and Class I histone deacetylases (HDACs) synergistically inhibits cell

- growth and enhances p21 expression in ovarian cancer. Poster Presentation, 2008 American Association for Cancer Research Annual Meeting, San Diego, CA, April 2008
- 27) Son DS, Parl A, **Khabele D**. Preferential effect of AKT-2 dependent signaling on cellular proliferation of ovarian cancer in response to EGF. Poster Presentation, 2009 American Association for Cancer Research Annual Meeting, Denver, CO April 2009
  - 28) Wilson A, Holson E, Bhaskara S, Carlise J, Hiebert S, Schreiber S and **Khabele D**. Histone H2AX phosphorylation and other DNA-damage response histone marks distinguish the anti-tumor effects of histone deacetylase inhibitors in ovarian cancer cells, Poster Presentation, American Association for Cancer Research Special Conference on Cancer Epigenetics, San Juan, Puerto Rico, January 2010
  - 29) Wilson A, Liu A, Edwards T, Williams M, Holson E, Bhaskara S, Hiebert S, Slaughter J, Fadare O, **Khabele D**. The pattern of H3K56 acetylation expression in ovarian cancer. Poster Presentation, Annual Meeting of the Society for Gynecologic Oncologist, Orlando, FL, March 2011
  - 30) Wilson A, Oshinko H, Yull F, **Khabele D**. A preclinical model for investigation of nuclear factor-kappa B inhibitors in ovarian cancer. Poster Presentation, American Association for Cancer Research Annual Meeting, Orlando, FL, April 2011
  - 31) **Khabele D**, Liu A, Wilson A, Fadare O, Crispens M. An orthotopic model of fallopian tube serous carcinoma. Abstract Presentation, Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 2011
  - 32) **Khabele D**. The Pattern of H3K56 acetylation in ovarian cancer. Oral Presentation, NCI Translational Science Meeting, Washington, DC, July 2011
  - 33) Wilson A and **Khabele D**. Romidepsin (FK228) combined with cisplatin enhances DNA damage response phosphorylation of gamma H2AX in ovarian cancer cells. Poster Presentation, Annual Meeting of the Society of Gynecologic Oncology, Austin, TX, March 2012
  - 34) Wilson A, Wass E, **Khabele D**. Olaparib and SAHA: a novel combination for targeting DNA damage response pathways in ovarian cancer cells. Poster Presentation, Annual Meeting of the Society of Gynecologic Oncology, Austin, TX, March 2012
  - 35) Wilson A, Lee H, Barham W, Chen L, Onishko H, **Khabele D**, Yull, Y. Investigating the patterns of nuclear factor-kappa B activity in the host-tumor microenvironment during ovarian cancer progression. Poster Presentation, American Association for Cancer Research Annual Meeting, Chicago, IL, April 2012
  - 36) Wilson A, Holson E, Wagner F, Schreiber S, **Khabele D**. Assessing the biological relevance of novel small molecule HDAC inhibitors in ovarian cancer cells. Annual Meeting of the Society of Black Academic Surgeons, Baltimore, MD, April 2012
  - 37) Wilson A, Liu A, Roland J, Fletcher S, Slaughter J, Crispens M, Gold M, Jones H, James S, Fadare O, **Khabele D**. Nucleophosmin expression in ovarian cancer. Abstract Presentation, Annual Meeting of the American Society of Clinical

- Oncology, Chicago, IL, June 2012
- 38) Wilson A, Sinaise L, Readus J, Park M, Lalani A, Saskowski J and **Khabele D**. Combination low dose 5-azacytidine (AZA) and romidepsin (FK228) therapy re-sensitizes ovarian cancer cells to cisplatin. Poster Presentation, Keystone Symposium, Santa Fe, NM, March 2013
  - 39) Wilson A, Sinaise L, Readus J, Park M, Lalani A, Saskowski J and **Khabele D**. Low dose 5-azacytidine (AZA) and romidepsin (FK228) epigenetic therapy re-sensitizes ovarian cancer cells to cisplatin. Poster Presentation, American Association for Cancer Research Annual Meeting, Chicago, IL, April 2013
  - 40) Wilson A, Saskowski J, Barham W, Tikhomirov O, Chen L, **Khabele D** and Yull F. Opposing effects of the NF-KB inhibitor thymoquinone in a syngeneic mouse model of ovarian cancer. Poster Presentation, American Association for Cancer Research Annual Meeting, Chicago, IL, April 2013
  - 41) **Khabele D**. Targeting epigenetic dysregulation to enhance cisplatin-mediated cytotoxicity in ovarian cancer. Oral Presentation, FASEB Meeting on HDACs Sirtuins and Reversible Acetylation in Signaling and Disease, Barga, Lucca, Italy, August 2013
  - 42) Wilson A, Holson E, Wagner F, Schreiber S, **Khabele D**. Assessing the biological relevance of novel small molecule HDAC inhibitors in ovarian cancer cells. Poster Presentation, American Association for Cancer Research Advances in Ovarian Cancer Research: From Concept to Clinic, Miami, FL, September 2013
  - 43) Beeghly-Fadiel A, Lovett L, Delahanty R, **Khabele D**, Zhang W. Resources for research: Identification and validation of ovarian cancer cases from the Synthetic Derivative. Poster Presentation, American Association for Cancer Research Advances in Ovarian Cancer Research: From Concept to Clinic, Miami, FL, September 2013
  - 44) Wilson A, Saskowski J, **Khabele D**. Preclinical testing of TR3 activators in cisplatin-resistant ovarian cancer. Poster Presentation, American Association for Cancer Research Advances in Ovarian Cancer Research: From Concept to Clinic, Miami, FL, September 2013
  - 45) Wilson A, Saskowski J, **Khabele D**, Hiebert S. The bromodomain inhibitor JQ1 enhances cisplatin-mediated cytotoxicity in ovarian cancer cells. Poster Presentation, American Association for Cancer Research Advances in Ovarian Cancer Research: From Concept to Clinic, Miami, FL, September 2013
  - 46) Huya-Koudiao D, Wilson, A, Saskowski J, **Khabele D**. Histone deacetylase 3 expression and cytoplasmic localization modulate apoptosis in ovarian cancer cells. Poster Presentation, American Association for Cancer Research Conference on The Science of Cancer Health Disparities, Atlanta, GA, December 2013
  - 47) Wilson A, Saskowski J, Garrett J, Arteaga C, **Khabele D**. Targeting PI3K/AKT signaling and the TR3/NR4A1 receptor in ovarian cancer. Poster Presentation, Annual Meeting of the Society of Gynecologic Oncology, Tampa FL, March 2014
  - 48) Wilson A, Lehmann B, Uddin M, Elleman A, Crews B, Saskowski, Pietenpol J, Marnett J, **Khabele D**. Cyclooxygenase-1 as a target for molecular imaging of high grade serous ovarian cancer. Poster Presentation, American Association for Cancer Research Annual Meeting, San Diego, CA, April 2014
  - 49) Huya-Koudiao D, Wilson A, Saskowski J, **Khabele D**. Histone deacetylase 3

- expression and cytoplasmic localization modulate apoptosis in ovarian cancer cells. Poster Presentation, Annual Meeting of the Society of Black Academic Surgeons, Philadelphia, PA, April 2014
- 50) Wilson, A, Beeghly-Fadiel A, Brian D. Lehmann, Li Q, Saskowski J, Smith S, Pietenpol J, Marnett LJ, **Khabele D**. Disrupting cyclooxygenase-1 activity in high-grade serous ovarian cancer. Poster Presentation, 10th Biennial Ovarian Cancer Research Symposium, Marsha Rivkin Center, Seattle, WA, September 2014
  - 51) Beeghly-Fadiel A, Holman G, Stansel S, Edwards G, Baeg E, Berke H, Delahanty R, **Khabele D**. Aspirin, NSAIDs, and Ovarian Cancer Survival from Electronic Medical Records. Poster Presentation, 10th Biennial Ovarian Cancer Research Symposium, Marsha Rivkin Center, Seattle, WA, September 2014
  - 52) Wilson A, Lehmann B, Saskowski J, Uddin M, Daniel C, Crews B, Zhao S, Li Q, Son D, Jennifer Pietenpol J, Marnett L, **Khabele D**. Cyclooxygenase-1 gene expression contributes to multiple oncogenic pathways in high grade serous ovarian cancer. Poster Presentation, American Association for Cancer Research Annual Meeting, Philadelphia, PA, April 2015
  - 53) Barham W, Tikhomirov O, Ortega R, Saskowski J, Thompson T, Wilson A, Blackwell T, Mirafzali Z **Khabele D**, Giorgio T, Yull F. A novel cancer therapeutic strategy: inducing cytotoxic functions in tumor-associated macrophages. Poster Presentation, American Association for Cancer Research Annual Meeting, Philadelphia, PA, April 2015
  - 54) Wilson A, Saskowski J, **Khabele, D**. The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to poly ADP ribose polymerase inhibitors via E2F1 downregulation. Poster Presentation, American Association for Cancer Research Special Conference - Chromatin and Epigenetics in Cancer, Atlanta, GA, September 2015
  - 55) Beeghly-Fadiel, A, El Ramahi M, Wilson A, Keene S, Fadare O, Crispens M, **Khabele, D**. The importance of cyclooxygenase 1 and 2 expression in ovarian cancer survival: Notable differences by histologic subtype. Poster Presentation, American Association for Cancer Research Special Conference - Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, Orlando, FL, October 2015
  - 56) Keene S, Stansel S, Clayton L, Jiang M, Aldrich M, Xu H, Warner J, Denny J, **Khabele D**, Beeghly-Fadiel A. Type 2 diabetes, metformin, and ovarian cancer survival: An analysis of tumor registry and medical record data. Poster Presentation, American Association for Cancer Research Special Conference - Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, Orlando, FL, October 2015
  - 57) Barham W, Wilson A, Ortega R, Saskowski J, Tikhomirov O, Giorgio T, **Khabele D**, Yull F. Targeted activation of macrophages to limit ovarian cancer progression. Poster Presentation, American Association for Cancer Research Special Conference - Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, Orlando, FL, October 2015
  - 58) Wilson A, Saskowski J, **Khabele, D**. The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to the cyclin-dependent kinase 2 inhibitor dinaciclib. Poster Presentation, American

- Association for Cancer Research Special Conference - Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, Orlando, FL, October 2015
- 59) Wilson A, Saskowski J, **Khabele, D**. The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to poly ADP ribose polymerase inhibitors via E2F1 downregulation. Poster Presentation, American Association for Cancer Research Special Conference - Advances in Ovarian Cancer Research: Exploiting Vulnerabilities. Orlando, FL, October 2015
  - 60) Hull P, Williams E, **Khabele D**, McAfee C, Sanderson M. Bug your doc - Get 3 shots! A culturally appropriate social marketing intervention to increase HPV vaccination. Poster Presentation, American Association for Cancer Research Meeting on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Atlanta, GA, November 2015
  - 61) Clayton L, Keene S, Stansel S, Jiang M, Aldrich M, Xu H, Warner J, Denny J, **Khabele D**, Beeghly-Fadiel A. Assessing metformin use and ovarian cancer survival from electronic medical records. Poster Presentation, American Association for Cancer Research Meeting on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Atlanta, GA, November 2015
  - 62) Cozzi G, Samuel J, Fromal J, Keene S, Crispens M, **Khabele D**, Beeghly-Fadiel A. Thrombocytosis, and epithelial ovarian cancer survival: relevant time frame of platelet count measurement and diagnostic threshold for thrombocytosis. Poster Presentation American Association for Cancer Research Annual Meeting, New Orleans, LA, April 2016
  - 63) Jiang X, Li H, Zhao P, Xie J, **Khabele D**, Xu J, Gore JC Assessment of early antimetabolic treatment response in ovarian cancer using temporal diffusion spectroscopy. Poster Presentation American Association for Cancer Research Annual Meeting, New Orleans, LA, April 2016
  - 64) Sarfo-Kantanka K, Wilson AJ, Alexandra Steck A, Jeanette Saskowski J, **Khabele D**. The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to poly ADP-ribose polymerase inhibitor. Olaparib. Poster Presentation American Association for Cancer Research Annual Meeting, New Orleans, LA, April 2016
  - 65) Foxx A, Zhu Y, Mitchel E, Pemmaraju M, **Khabele D**, Griffin M. Decline in Cervical Cancer Screening and Follow-up Procedures in Women Age <21 years following New Screening Guidelines. Oral Poster Presentation American College of Obstetricians and Gynecologists Annual Meeting, Washington, DC, April 2016
  - 66) Wilson A, Thompson J, Osman A, Saskowski, **Khabele, D**. The bromodomain inhibitor JQ1 sensitizes homologous recombination proficient ovarian cancer cells to the PARP inhibitor olaparib. Poster Presentation, The Rivkin Center for Ovarian Cancer & the American Association for Cancer Research 11<sup>th</sup> Biennial Ovarian Cancer Research Symposium, Seattle, Washington, September 2016
  - 67) Toole H, Levinson R, Cozzi G, Deng A, Fromal J, Snyder M, **Khabele D**, Beeghly-Fadiel A. Blood type, ABO genetic variants, and ovarian cancer survival. The Rivkin Center for Ovarian Cancer & the American Association for Cancer Research 11<sup>th</sup> Biennial Ovarian Cancer Research Symposium, Seattle, Washington, September 2016

- 68) Wilson A, Thompson J, Osman A, Saskowski, **Khabele, D**. The bromodomain inhibitor JQ1 sensitizes homologous recombination proficient ovarian cancer cells to the PARP inhibitor olaparib. Poster Presentation, American Association for Cancer Research Annual Meeting, Washington, DC, April 2017
- 69) Wilson A, Hoover A, Harris W, Liu E, **Khabele D**, Yull F. Bromodomain inhibition in ovarian cancer and the tumor microenvironment to improve PARP inhibitor response. American Association for Cancer Research Annual Meeting, Chicago, IL, April 2018.
- 70) Giri A, Levinson R, Keene S, Holman G, Smith S, Clayton L, Lovett W, Stansel S, Bringham Snyder M, Fromal J, Cozzi G, **Khabele D**, Beeghly-Fadiel A. Preliminary results from the Pharmacogenetics Ovarian Cancer Knowledge to Individualize Treatment (POCKIT) Study. American Association for Cancer Research Annual Meeting, Chicago, IL, April 2018
- 71) Liu E, Hoover A, Harris W, Barham W, Tikhomirov O, **Khabele D**, Mirafzali Z, Giorgio T, Wilson A, Yull F. Modulation of NF-kappaB signaling to optimize anti-tumor characteristics in macrophages. American Association for Cancer Research Annual Meeting, Chicago, IL, April 2018
- 72) Beeghly-Fadiel A, Cooks J, Chase D, Crispens M, **Khabele D**, Wilson A. Prognostic Significance of NR4A1/TR3 Expression in Ovarian Cancer. The Rivkin Center Ovarian Cancer Research Meeting. Seattle, WA, September 2018
- 73) Wilson A, Hoover A, Harris W, Liu E, **Khabele D**, F Yull. Bromodomain inhibition in ovarian cancer and the tumor microenvironment. The Rivkin Center for Ovarian Cancer & the American Association for Cancer Research 12th Biennial Ovarian Cancer Research Symposium, Seattle, Washington, September 2018
- 74) Petersen, S, Wilson A, **Khabele D**. CCNE1 and BRD4 expression and platinum resistance in high-grade serous ovarian cancers. The Rivkin Center for Ovarian Cancer & the American Association for Cancer Research 12<sup>th</sup> Biennial Ovarian Cancer Research Symposium, Seattle, Washington, September 2018
- 75) Beeghly-Fadiel A, Cooks J, Chase D, Crispens M, **Khabele D**, Wilson A. NR4A1 inhibition as a novel strategy to sensitize homologous recombination-proficient ovarian cancer to PARP inhibitors. Society of Gynecologic Oncology Annual Meeting, Honolulu, HI, March 2019
- 76) Petersen, S, Wilson A, **Khabele D**. CCNE1 and BRD4 expression and platinum resistance in high-grade serous ovarian cancers. Society of Gynecologic Oncology Annual Meeting, Honolulu, HI, March 2019
- 77) Gupta V, Petersen S, Hirst J, Roby K, Pathak H, Kusch M, Wilson A, Godwin A, **Khabele D**. Entinostat induces PARPi sensitivity across multiple ovarian cancer models. American Association for Cancer Research Virtual Meeting, June 2020
- 78) Standing D, Gunewardena S, Sayed A, Pritchard M, Pathak H, Godwin A, Petersen S, **Khabele D**, Roy J, Dandawate P, Weir S, Anant S. IRAK1: A novel TOLLway to target ovarian cancer. American Association for Cancer Research Annual Meeting, New Orleans, Louisiana, April 2021
- 79) Woodard T, Gupta V, Miceska S, Fashemi B, Zhang W, **Khabele D**. Entinostat restores responsiveness to Olaparib in ID8 TP53 null and ID8 TP53 null/BRCA2 null mouse ovarian cancer cell lines. American

- Association for Cancer Research Annual Meeting, New Orleans, Louisiana, April 2021
- 80) Bruce S, Cho K, Noia H, Lomonosova E, Stock E, Opllt A, Blachut B, Mullen M, Kuroki L, Hagemann A, McCourt C, Thaker P, **Khabele D**, Powell M, Mutch D, Shriver L, Patti G, Fuh K. LB081 - GAS6-AXL inhibition by AVB-500 overcomes resistance to paclitaxel in endometrial cancer by decreasing tumor cell glycolysis. American Association for Cancer Research Annual Meeting, New Orleans, Louisiana, April 2021
- 81) Mullen M, Van Biljon L, Quinn J, Greenwade M, Opara G, Noia H, Hagemann I, Hagemann A, Kuroki L, McCourt C, Thaker P, Powell M, Mutch D, **Khabele D**, Fuh K. Tumor, and stromal AXL expression regulate ovarian cancer metastasis. American Association for Cancer Research Annual Meeting, New Orleans, Louisiana, April 2021
- 82) Gupta V, Roby K, Pathak H, Godwin A, Gunewardena S, **Khabele D**. Rebastinib, a TIE2 antagonist, improves chemotherapy response in homologous recombination proficient epithelial ovarian cancer murine models. American Association for Cancer Research Annual Meeting, New Orleans, Louisiana, April 2021
- 83) Fashemi B, van Biljon L, Gupta V, Woodard T, Graham O, Rodriguez J, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell D, Mullen M, Bitler B, **Khabele D**. Developing Patient and Murine Derived Organoid Models of Ovarian Cancer'. CRepHS Seminar Series January 27, 2023
- 84) Fashemi B, van Biljon L, Gupta V, Woodard T, Graham O, Rodriguez J, Kuroki L, Hagemann A, McCourt C, Thaker P, Massad Jr LS, Mutch D, Powell M, Bitler B, Mullen M, **Khabele D**. Entinostat restores responsiveness to olaparib in two in vitro models of PARPi resistant ovarian cancer cells. Society for Reproductive Investigation Annual Meeting March 21-25, 2023
- 85) Fashemi B, van Biljon L, Gupta V, Woodard T, Graham O, Rodriguez J, Kuroki L, Hagemann A, McCourt C, Thaker P, Massad Jr. LS, Mutch D, Powell M, Bitler B, Mullen M, **Khabele D**. Entinostat restores responsiveness to olaparib in two in vitro models of homologous recombination proficient ovarian cancer cells. Society of Gynecologic Oncology Annual Meeting March 25-28, 2023
- 86) Fashemi B, van Biljon L, Graham O, Rodriguez J, Blachut B, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell M, Fuh K, **Khabele D**., Mullen M. Development and Assessment of Patient-Derived Ovarian Cancer Organoid Living Tissue Bank.' Society of Gynecologic Oncology Annual Meeting March 25-28, 2023
- 87) Fashemi B, van Biljon L, Gupta V, Woodard T, Mullen M, Bitler B, **Khabele D**. Entinostat restores sensitivity to olaparib in two in vitro models of PARPi-resistant ovarian cancer cells. American Association for Cancer Research Annual Meeting April 14-19, 2023
- 88) Gupta V, Woodard T, Miceska S, Fashemi B, Chadchanb S, Zhang W, Roby K, Wilson A, Yull F, Crispens M, Naik S, Smirnov A, Stallings C, **Khabele D**. Olaparib combined with entinostat exerts differential effects on tumor-associated macrophages in tumors compared to ascites in syngeneic HR-proficient murine models of ovarian cancer'. American Association for Cancer Research Annual

Meeting April 14-19, 2023

- 89) Fashemi B, van Biljon L, Gupta V, Woodard T, Graham O, Rodriguez J, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell M, Mullen M, Bitler B, **Khabele D**. Developing Patient and Murine Derived Organoid Models of Ovarian Cancer'. Dr. David Rothman Research Day April 26, 2023
- 90) Ota Y, Gupta V, Fashemi B, Mitra S, Zhang W, Akande M, Wallerstein SE, Kuroki LM, McCourt CK, Hagemann AR, Thaker PH, Mutch DG, Hagemann IS, Powell MA, Bitler BG, Fuh KC, Mullen M, **Khabele D**. RAD52 is a potential therapeutic target in PARP inhibitor resistant BRCA deficient ovarian cancer. Society of Gynecologic Oncology's Annual Meeting on Women's Cancer. San Diego, CA. 03/2024.
- 91) Gupta V, Fashemi B, Zhang W, Wilson A, Yull F, Crispens M, Mullen M, **Khabele D**. Selective disruption of HDAC3 in ovarian cancer. Society for Reproductive Investigations. Vancouver, BC. 03/2024.
- 92) Fashemi B, Gupta V, Akande M, Ota Y, Mitra S, Bitler B, **Khabele D**. Selective HDAC3 inhibition re-sensitizes PARPi-resistant ovarian cancer cells to olaparib. American Association for Cancer Research. San Diego, CA. 04/2024.
- 93) Gupta V, Liu H, Zhang R, Onken M, Wilson A, Yull F, Crispens M, Mullen M, **Khabele D**. Entinostat alters cell cycle in ovarian cancer cells. American Association of Cancer Research. San Diego, CA. 04/2024
- 94) Fashemi B, Gupta V, Ota Y, Akande M, Mullen M, **Khabele D**. Single-cell transcriptomic signatures of ovarian cancer patient-derived organoids and patient tumors. National Black Postdoctoral Association Leadership Symposium. Virtual. 10/2024.
- 95) Ota Y, Gupta V, Fashemi B, Akande M, **Khabele D**. RAD52 is a potential therapeutic target for PARP inhibitor resistant BRCA-deficient ovarian cancer. Siteman Cancer Research Symposium. St. Louis, MO. 11/2024.
- 96) Fashemi B, Gupta V, Ota Y, Akande M, Mullen M, **Khabele D**. Single-cell signatures of high-grade serous ovarian cancer patient-derived organoids. Center for Reproductive Health Sciences. Seminar Series, Washington University School of Medicine. St. Louis, MO. 02/2025.
- 97) Ota Y, Gupta V, Fashemi B, Akande M, Babu P, Sanders BE, Kuroki LM, McCourt CK, Hagemann AR, Hagemann IS, Thaker PH, Mutch DG, Powell MA, Verma P, Kraiss J, Bitler BG, Fuh KC, Mullen M, **Khabele D**. RAD52 inhibition enhances olaparib efficacy in PARP inhibitor-resistant BRCA-deficient ovarian cancer. Society of Gynecologic Oncology's Annual Meeting on Women's Cancer. Seattle, Washington. 03/2025.
- 98) Fashemi B, Gupta V, Ota Y, Akande M, Mullen M, **Khabele D**. Single-cell signatures of high-grade serous ovarian cancer patient-derived organoids. Keystone Symposium: Regenerative Biology of the Female Reproductive System. Breckenridge, CO. 4/2025.
- 99) Fashemi B, Gupta V, Ota Y, Akande M, Mullen M, **Khabele D**. Single-cell signatures of high-grade serous ovarian cancer patient-derived organoids. American Association for Cancer Research. Chicago, IL. 4/2025

100)Gupta V, Akande M, Babu P, Ota Y, Fashemi B, Xaio Y, Zhang G, Mullen M, **Khabele D**. Precision targeting of HDAC3 in ovarian cancer. American Association of Cancer Research. Chicago, IL. 04/2025.